id	sid	tid	token	lemma	pos
eyereports-42	1	1	hrev_master	hrev_master	NOUN
eyereports-42	2	1	[	[	X
eyereports-42	2	2	page	page	NOUN
eyereports-42	2	3	12	12	NUM
eyereports-42	2	4	]	]	PUNCT
eyereports-42	3	1	[	[	X
eyereports-42	3	2	eye	eye	NOUN
eyereports-42	3	3	reports	report	VERB
eyereports-42	3	4	2011	2011	NUM
eyereports-42	3	5	;	;	PUNCT
eyereports-42	3	6	1	1	NUM
eyereports-42	3	7	:	:	PUNCT
eyereports-42	3	8	e5	e5	X
eyereports-42	3	9	]	]	X
eyereports-42	3	10	what	what	PRON
eyereports-42	3	11	are	be	AUX
eyereports-42	3	12	the	the	DET
eyereports-42	3	13	half	half	ADJ
eyereports-42	3	14	-	-	PUNCT
eyereports-42	3	15	lives	life	NOUN
eyereports-42	3	16	of	of	ADP
eyereports-42	3	17	ranibizumab	ranibizumab	NOUN
eyereports-42	3	18	and	and	CCONJ
eyereports-42	3	19	aflibercept	aflibercept	NOUN
eyereports-42	3	20	(	(	PUNCT
eyereports-42	3	21	vegf	vegf	PROPN
eyereports-42	3	22	trap	trap	NOUN
eyereports-42	3	23	-	-	PUNCT
eyereports-42	3	24	eye	eye	NOUN
eyereports-42	3	25	)	)	PUNCT
eyereports-42	3	26	in	in	ADP
eyereports-42	3	27	human	human	ADJ
eyereports-42	3	28	eyes	eye	NOUN
eyereports-42	3	29	?	?	PUNCT
eyereports-42	4	1	calculations	calculation	NOUN
eyereports-42	4	2	with	with	ADP
eyereports-42	4	3	a	a	DET
eyereports-42	4	4	mathematical	mathematical	ADJ
eyereports-42	4	5	model	model	NOUN
eyereports-42	4	6	michael	michael	PROPN
eyereports-42	4	7	w.	w.	PROPN
eyereports-42	4	8	stewart	stewart	PROPN
eyereports-42	4	9	mayo	mayo	PROPN
eyereports-42	4	10	clinic	clinic	PROPN
eyereports-42	4	11	school	school	NOUN
eyereports-42	4	12	of	of	ADP
eyereports-42	4	13	medicine	medicine	NOUN
eyereports-42	4	14	,	,	PUNCT
eyereports-42	4	15	jacksonville	jacksonville	PROPN
eyereports-42	4	16	,	,	PUNCT
eyereports-42	4	17	fl	fl	PROPN
eyereports-42	4	18	,	,	PUNCT
eyereports-42	4	19	usa	usa	PROPN
eyereports-42	4	20	abstract	abstract	NOUN
eyereports-42	4	21	the	the	DET
eyereports-42	4	22	aim	aim	NOUN
eyereports-42	4	23	of	of	ADP
eyereports-42	4	24	the	the	DET
eyereports-42	4	25	article	article	NOUN
eyereports-42	4	26	is	be	AUX
eyereports-42	4	27	to	to	PART
eyereports-42	4	28	estimate	estimate	VERB
eyereports-42	4	29	the	the	DET
eyereports-42	4	30	intravitreal	intravitreal	ADJ
eyereports-42	4	31	half	half	ADJ
eyereports-42	4	32	-	-	PUNCT
eyereports-42	4	33	lives	life	NOUN
eyereports-42	4	34	of	of	ADP
eyereports-42	4	35	ranibizumab	ranibizumab	NOUN
eyereports-42	4	36	and	and	CCONJ
eyereports-42	4	37	aflibercept	aflibercept	NOUN
eyereports-42	4	38	(	(	PUNCT
eyereports-42	4	39	vegf	vegf	PROPN
eyereports-42	4	40	trap	trap	NOUN
eyereports-42	4	41	-	-	PUNCT
eyereports-42	4	42	eye	eye	NOUN
eyereports-42	4	43	;	;	PUNCT
eyereports-42	4	44	vte	vte	NOUN
eyereports-42	4	45	)	)	PUNCT
eyereports-42	4	46	in	in	ADP
eyereports-42	4	47	human	human	ADJ
eyereports-42	4	48	eyes	eye	NOUN
eyereports-42	4	49	.	.	PUNCT
eyereports-42	5	1	using	use	VERB
eyereports-42	5	2	a	a	DET
eyereports-42	5	3	published	publish	VERB
eyereports-42	5	4	mathematical	mathematical	ADJ
eyereports-42	5	5	model	model	NOUN
eyereports-42	5	6	for	for	ADP
eyereports-42	5	7	rabbits	rabbit	NOUN
eyereports-42	5	8	,	,	PUNCT
eyereports-42	5	9	the	the	DET
eyereports-42	5	10	intravitreal	intravitreal	ADJ
eyereports-42	5	11	half	half	ADJ
eyereports-42	5	12	-	-	PUNCT
eyereports-42	5	13	lives	life	NOUN
eyereports-42	5	14	of	of	ADP
eyereports-42	5	15	ranibizumab	ranibizumab	NOUN
eyereports-42	5	16	and	and	CCONJ
eyereports-42	5	17	bevacizumab	bevacizumab	NOUN
eyereports-42	5	18	were	be	AUX
eyereports-42	5	19	calculated	calculate	VERB
eyereports-42	5	20	and	and	CCONJ
eyereports-42	5	21	compared	compare	VERB
eyereports-42	5	22	to	to	ADP
eyereports-42	5	23	empirical	empirical	ADJ
eyereports-42	5	24	data	datum	NOUN
eyereports-42	5	25	.	.	PUNCT
eyereports-42	6	1	the	the	DET
eyereports-42	6	2	slope	slope	NOUN
eyereports-42	6	3	coefficient	coefficient	NOUN
eyereports-42	6	4	within	within	ADP
eyereports-42	6	5	the	the	DET
eyereports-42	6	6	model	model	NOUN
eyereports-42	6	7	was	be	AUX
eyereports-42	6	8	changed	change	VERB
eyereports-42	6	9	to	to	PART
eyereports-42	6	10	set	set	VERB
eyereports-42	6	11	the	the	DET
eyereports-42	6	12	bevacizumab	bevacizumab	NOUN
eyereports-42	6	13	output	output	NOUN
eyereports-42	6	14	equal	equal	ADJ
eyereports-42	6	15	to	to	ADP
eyereports-42	6	16	experimental	experimental	ADJ
eyereports-42	6	17	values	value	NOUN
eyereports-42	6	18	to	to	PART
eyereports-42	6	19	meet	meet	VERB
eyereports-42	6	20	3	3	NUM
eyereports-42	6	21	goals	goal	NOUN
eyereports-42	6	22	:	:	PUNCT
eyereports-42	6	23	firstly	firstly	ADV
eyereports-42	6	24	,	,	PUNCT
eyereports-42	6	25	to	to	PART
eyereports-42	6	26	validate	validate	VERB
eyereports-42	6	27	the	the	DET
eyereports-42	6	28	model	model	NOUN
eyereports-42	6	29	in	in	ADP
eyereports-42	6	30	rabbit	rabbit	NOUN
eyereports-42	6	31	eyes	eye	NOUN
eyereports-42	6	32	;	;	PUNCT
eyereports-42	6	33	secondly	secondly	ADV
eyereports-42	6	34	,	,	PUNCT
eyereports-42	6	35	to	to	PART
eyereports-42	6	36	test	test	VERB
eyereports-42	6	37	the	the	DET
eyereports-42	6	38	mutability	mutability	NOUN
eyereports-42	6	39	of	of	ADP
eyereports-42	6	40	the	the	DET
eyereports-42	6	41	model	model	NOUN
eyereports-42	6	42	to	to	PART
eyereports-42	6	43	monkey	monkey	VERB
eyereports-42	6	44	eyes	eye	NOUN
eyereports-42	6	45	;	;	PUNCT
eyereports-42	6	46	thirdly	thirdly	ADV
eyereports-42	6	47	,	,	PUNCT
eyereports-42	6	48	to	to	PART
eyereports-42	6	49	calculate	calculate	VERB
eyereports-42	6	50	the	the	DET
eyereports-42	6	51	half	half	ADJ
eyereports-42	6	52	-	-	PUNCT
eyereports-42	6	53	lives	life	NOUN
eyereports-42	6	54	of	of	ADP
eyereports-42	6	55	ranibizumab	ranibizumab	NOUN
eyereports-42	6	56	and	and	CCONJ
eyereports-42	6	57	the	the	DET
eyereports-42	6	58	vte	vte	NOUN
eyereports-42	6	59	in	in	ADP
eyereports-42	6	60	human	human	ADJ
eyereports-42	6	61	eyes	eye	NOUN
eyereports-42	6	62	.	.	PUNCT
eyereports-42	7	1	the	the	DET
eyereports-42	7	2	half	half	ADJ
eyereports-42	7	3	-	-	PUNCT
eyereports-42	7	4	life	life	NOUN
eyereports-42	7	5	calculations	calculation	NOUN
eyereports-42	7	6	for	for	ADP
eyereports-42	7	7	ranibizumab	ranibizumab	NOUN
eyereports-42	7	8	deviate	deviate	NOUN
eyereports-42	7	9	from	from	ADP
eyereports-42	7	10	published	publish	VERB
eyereports-42	7	11	rabbit	rabbit	NOUN
eyereports-42	7	12	and	and	CCONJ
eyereports-42	7	13	monkey	monkey	NOUN
eyereports-42	7	14	values	value	NOUN
eyereports-42	7	15	by	by	ADP
eyereports-42	7	16	only	only	ADV
eyereports-42	7	17	8.3	8.3	NUM
eyereports-42	7	18	%	%	NOUN
eyereports-42	7	19	and	and	CCONJ
eyereports-42	7	20	4.2	4.2	NUM
eyereports-42	7	21	%	%	NOUN
eyereports-42	7	22	.	.	PUNCT
eyereports-42	8	1	using	use	VERB
eyereports-42	8	2	the	the	DET
eyereports-42	8	3	experimentally	experimentally	ADV
eyereports-42	8	4	determined	determine	VERB
eyereports-42	8	5	half	half	ADJ
eyereports-42	8	6	-	-	PUNCT
eyereports-42	8	7	life	life	NOUN
eyereports-42	8	8	of	of	ADP
eyereports-42	8	9	bevacizumab	bevacizumab	NOUN
eyereports-42	8	10	in	in	ADP
eyereports-42	8	11	human	human	ADJ
eyereports-42	8	12	eyes	eye	NOUN
eyereports-42	8	13	(	(	PUNCT
eyereports-42	8	14	8.25	8.25	NUM
eyereports-42	8	15	days	day	NOUN
eyereports-42	8	16	)	)	PUNCT
eyereports-42	8	17	to	to	PART
eyereports-42	8	18	set	set	VERB
eyereports-42	8	19	the	the	DET
eyereports-42	8	20	equation	equation	NOUN
eyereports-42	8	21	,	,	PUNCT
eyereports-42	8	22	the	the	DET
eyereports-42	8	23	half	half	ADJ
eyereports-42	8	24	-	-	PUNCT
eyereports-42	8	25	lives	life	NOUN
eyereports-42	8	26	of	of	ADP
eyereports-42	8	27	ranibizumab	ranibizumab	NOUN
eyereports-42	8	28	and	and	CCONJ
eyereports-42	8	29	the	the	DET
eyereports-42	8	30	vte	vte	NOUN
eyereports-42	8	31	are	be	AUX
eyereports-42	8	32	calculated	calculate	VERB
eyereports-42	8	33	to	to	PART
eyereports-42	8	34	be	be	AUX
eyereports-42	8	35	4.75	4.75	NUM
eyereports-42	8	36	days	day	NOUN
eyereports-42	8	37	and	and	CCONJ
eyereports-42	8	38	7.13	7.13	NUM
eyereports-42	8	39	days	day	NOUN
eyereports-42	8	40	in	in	ADP
eyereports-42	8	41	human	human	ADJ
eyereports-42	8	42	eyes	eye	NOUN
eyereports-42	8	43	.	.	PUNCT
eyereports-42	9	1	the	the	DET
eyereports-42	9	2	intraocular	intraocular	ADJ
eyereports-42	9	3	half	half	ADJ
eyereports-42	9	4	-	-	PUNCT
eyereports-42	9	5	lives	life	NOUN
eyereports-42	9	6	of	of	ADP
eyereports-42	9	7	ranibizumab	ranibizumab	NOUN
eyereports-42	9	8	and	and	CCONJ
eyereports-42	9	9	the	the	DET
eyereports-42	9	10	vte	vte	NOUN
eyereports-42	9	11	are	be	AUX
eyereports-42	9	12	estimated	estimate	VERB
eyereports-42	9	13	using	use	VERB
eyereports-42	9	14	existing	exist	VERB
eyereports-42	9	15	published	publish	VERB
eyereports-42	9	16	animal	animal	NOUN
eyereports-42	9	17	and	and	CCONJ
eyereports-42	9	18	human	human	ADJ
eyereports-42	9	19	data	datum	NOUN
eyereports-42	9	20	and	and	CCONJ
eyereports-42	9	21	a	a	DET
eyereports-42	9	22	mathematical	mathematical	ADJ
eyereports-42	9	23	model	model	NOUN
eyereports-42	9	24	.	.	PUNCT
eyereports-42	10	1	the	the	DET
eyereports-42	10	2	validity	validity	NOUN
eyereports-42	10	3	of	of	ADP
eyereports-42	10	4	these	these	DET
eyereports-42	10	5	half	half	ADJ
eyereports-42	10	6	-	-	PUNCT
eyereports-42	10	7	lives	life	NOUN
eyereports-42	10	8	and	and	CCONJ
eyereports-42	10	9	binding	bind	VERB
eyereports-42	10	10	activities	activity	NOUN
eyereports-42	10	11	,	,	PUNCT
eyereports-42	10	12	however	however	ADV
eyereports-42	10	13	,	,	PUNCT
eyereports-42	10	14	awaits	await	VERB
eyereports-42	10	15	clinical	clinical	ADJ
eyereports-42	10	16	correlation	correlation	NOUN
eyereports-42	10	17	.	.	PUNCT
eyereports-42	11	1	introduction	introduction	NOUN
eyereports-42	11	2	antibody	antibody	NOUN
eyereports-42	11	3	based	base	VERB
eyereports-42	11	4	anti	anti	ADJ
eyereports-42	11	5	-	-	ADJ
eyereports-42	11	6	vegf	vegf	ADJ
eyereports-42	11	7	drugs	drug	NOUN
eyereports-42	11	8	have	have	AUX
eyereports-42	11	9	become	become	VERB
eyereports-42	11	10	standard	standard	ADJ
eyereports-42	11	11	of	of	ADP
eyereports-42	11	12	care	care	NOUN
eyereports-42	11	13	for	for	ADP
eyereports-42	11	14	the	the	DET
eyereports-42	11	15	treatment	treatment	NOUN
eyereports-42	11	16	of	of	ADP
eyereports-42	11	17	exudative	exudative	ADJ
eyereports-42	11	18	age	age	NOUN
eyereports-42	11	19	-	-	PUNCT
eyereports-42	11	20	related	relate	VERB
eyereports-42	11	21	macular	macular	ADJ
eyereports-42	11	22	degeneration	degeneration	NOUN
eyereports-42	11	23	and	and	CCONJ
eyereports-42	11	24	are	be	AUX
eyereports-42	11	25	frequently	frequently	ADV
eyereports-42	11	26	administered	administer	VERB
eyereports-42	11	27	for	for	ADP
eyereports-42	11	28	diabetic	diabetic	ADJ
eyereports-42	11	29	retinopathy	retinopathy	ADJ
eyereports-42	11	30	and	and	CCONJ
eyereports-42	11	31	retinal	retinal	ADJ
eyereports-42	11	32	vein	vein	ADJ
eyereports-42	11	33	occlusions	occlusion	NOUN
eyereports-42	11	34	.	.	PUNCT
eyereports-42	12	1	the	the	DET
eyereports-42	12	2	view	view	NOUN
eyereports-42	12	3	studies	study	NOUN
eyereports-42	12	4	showed	show	VERB
eyereports-42	12	5	that	that	SCONJ
eyereports-42	12	6	ranibizumab	ranibizumab	NOUN
eyereports-42	12	7	and	and	CCONJ
eyereports-42	12	8	the	the	DET
eyereports-42	12	9	aflibercept	aflibercept	NOUN
eyereports-42	12	10	(	(	PUNCT
eyereports-42	12	11	vegf	vegf	PROPN
eyereports-42	12	12	trap	trap	NOUN
eyereports-42	12	13	-	-	PUNCT
eyereports-42	12	14	eye	eye	NOUN
eyereports-42	12	15	;	;	PUNCT
eyereports-42	12	16	vte	vte	NOUN
eyereports-42	12	17	)	)	PUNCT
eyereports-42	12	18	had	have	VERB
eyereports-42	12	19	comparable	comparable	ADJ
eyereports-42	12	20	peak	peak	NOUN
eyereports-42	12	21	clinical	clinical	ADJ
eyereports-42	12	22	effects	effect	NOUN
eyereports-42	12	23	(	(	PUNCT
eyereports-42	12	24	heier	heier	PROPN
eyereports-42	12	25	j	j	PROPN
eyereports-42	12	26	,	,	PUNCT
eyereports-42	12	27	presen	presen	PROPN
eyereports-42	12	28	tation	tation	PROPN
eyereports-42	12	29	,	,	PUNCT
eyereports-42	12	30	angiogenesis	angiogenesis	PROPN
eyereports-42	12	31	,	,	PUNCT
eyereports-42	12	32	miami	miami	PROPN
eyereports-42	12	33	,	,	PUNCT
eyereports-42	12	34	fl	fl	PROPN
eyereports-42	12	35	,	,	PUNCT
eyereports-42	12	36	february	february	PROPN
eyereports-42	12	37	11	11	NUM
eyereports-42	12	38	,	,	PUNCT
eyereports-42	12	39	2011	2011	NUM
eyereports-42	12	40	;	;	PUNCT
eyereports-42	12	41	smith	smith	PROPN
eyereports-42	12	42	urfurth	urfurth	PROPN
eyereports-42	12	43	u	u	PROPN
eyereports-42	12	44	,	,	PUNCT
eyereports-42	12	45	presentation	presentation	NOUN
eyereports-42	12	46	,	,	PUNCT
eyereports-42	12	47	angiogenesis	angiogenesis	PROPN
eyereports-42	12	48	,	,	PUNCT
eyereports-42	12	49	miami	miami	PROPN
eyereports-42	12	50	,	,	PUNCT
eyereports-42	12	51	fl	fl	PROPN
eyereports-42	12	52	,	,	PUNCT
eyereports-42	12	53	february	february	PROPN
eyereports-42	12	54	11	11	NUM
eyereports-42	12	55	,	,	PUNCT
eyereports-42	12	56	2011	2011	NUM
eyereports-42	12	57	)	)	PUNCT
eyereports-42	12	58	suggesting	suggest	VERB
eyereports-42	12	59	that	that	SCONJ
eyereports-42	12	60	the	the	DET
eyereports-42	12	61	maximum	maximum	ADJ
eyereports-42	12	62	clinical	clinical	ADJ
eyereports-42	12	63	response	response	NOUN
eyereports-42	12	64	achievable	achievable	ADJ
eyereports-42	12	65	with	with	ADP
eyereports-42	12	66	anti	anti	ADJ
eyereports-42	12	67	-	-	ADJ
eyereports-42	12	68	vegf	vegf	ADJ
eyereports-42	12	69	monotherapy	monotherapy	NOUN
eyereports-42	12	70	in	in	ADP
eyereports-42	12	71	a	a	DET
eyereports-42	12	72	study	study	NOUN
eyereports-42	12	73	population	population	NOUN
eyereports-42	12	74	may	may	AUX
eyereports-42	12	75	have	have	AUX
eyereports-42	12	76	been	be	AUX
eyereports-42	12	77	reached	reach	VERB
eyereports-42	12	78	by	by	ADP
eyereports-42	12	79	the	the	DET
eyereports-42	12	80	currently	currently	ADV
eyereports-42	12	81	available	available	ADJ
eyereports-42	12	82	drugs	drug	NOUN
eyereports-42	12	83	.	.	PUNCT
eyereports-42	13	1	new	new	ADJ
eyereports-42	13	2	anti	anti	ADJ
eyereports-42	13	3	-	-	ADJ
eyereports-42	13	4	vegf	vegf	ADJ
eyereports-42	13	5	agents	agent	NOUN
eyereports-42	13	6	may	may	AUX
eyereports-42	13	7	need	need	VERB
eyereports-42	13	8	to	to	PART
eyereports-42	13	9	be	be	AUX
eyereports-42	13	10	differentiated	differentiate	VERB
eyereports-42	13	11	more	more	ADV
eyereports-42	13	12	by	by	ADP
eyereports-42	13	13	their	their	PRON
eyereports-42	13	14	duration	duration	NOUN
eyereports-42	13	15	of	of	ADP
eyereports-42	13	16	action	action	NOUN
eyereports-42	13	17	than	than	SCONJ
eyereports-42	13	18	by	by	ADP
eyereports-42	13	19	their	their	PRON
eyereports-42	13	20	peak	peak	NOUN
eyereports-42	13	21	clinical	clinical	VERB
eyereports-42	13	22	effect.the	effect.the	DET
eyereports-42	13	23	duration	duration	NOUN
eyereports-42	13	24	of	of	ADP
eyereports-42	13	25	clinical	clinical	ADJ
eyereports-42	13	26	action	action	NOUN
eyereports-42	13	27	of	of	ADP
eyereports-42	13	28	anti	anti	ADJ
eyereports-42	13	29	-	-	ADJ
eyereports-42	13	30	vegf	vegf	ADJ
eyereports-42	13	31	drugs	drug	NOUN
eyereports-42	13	32	is	be	AUX
eyereports-42	13	33	determined	determine	VERB
eyereports-42	13	34	by	by	ADP
eyereports-42	13	35	a	a	DET
eyereports-42	13	36	combination	combination	NOUN
eyereports-42	13	37	of	of	ADP
eyereports-42	13	38	binding	bind	VERB
eyereports-42	13	39	strength	strength	NOUN
eyereports-42	13	40	and	and	CCONJ
eyereports-42	13	41	intraocular	intraocular	ADJ
eyereports-42	13	42	half	half	ADJ
eyereports-42	13	43	-	-	PUNCT
eyereports-42	13	44	life.1,2	life.1,2	NOUN
eyereports-42	13	45	the	the	DET
eyereports-42	13	46	intravitreal	intravitreal	ADJ
eyereports-42	13	47	half	half	ADJ
eyereports-42	13	48	-	-	PUNCT
eyereports-42	13	49	life	life	NOUN
eyereports-42	13	50	of	of	ADP
eyereports-42	13	51	most	most	ADJ
eyereports-42	13	52	drugs	drug	NOUN
eyereports-42	13	53	is	be	AUX
eyereports-42	13	54	first	first	ADV
eyereports-42	13	55	determined	determined	ADJ
eyereports-42	13	56	in	in	ADP
eyereports-42	13	57	animal	animal	NOUN
eyereports-42	13	58	models	model	NOUN
eyereports-42	13	59	,	,	PUNCT
eyereports-42	13	60	usually	usually	ADV
eyereports-42	13	61	rabbit	rabbit	NOUN
eyereports-42	13	62	and/or	and/or	CCONJ
eyereports-42	13	63	monkey	monkey	NOUN
eyereports-42	13	64	,	,	PUNCT
eyereports-42	13	65	and	and	CCONJ
eyereports-42	13	66	then	then	ADV
eyereports-42	13	67	in	in	ADP
eyereports-42	13	68	humans	human	NOUN
eyereports-42	13	69	during	during	ADP
eyereports-42	13	70	phase	phase	NOUN
eyereports-42	13	71	i	i	PROPN
eyereports-42	13	72	-	-	PUNCT
eyereports-42	13	73	iii	iii	NUM
eyereports-42	13	74	trials	trial	NOUN
eyereports-42	13	75	or	or	CCONJ
eyereports-42	13	76	postapproval	postapproval	NOUN
eyereports-42	13	77	.	.	PUNCT
eyereports-42	14	1	pharmacokinetic	pharmacokinetic	ADJ
eyereports-42	14	2	studies	study	NOUN
eyereports-42	14	3	in	in	ADP
eyereports-42	14	4	human	human	ADJ
eyereports-42	14	5	eyes	eye	NOUN
eyereports-42	14	6	usually	usually	ADV
eyereports-42	14	7	consist	consist	VERB
eyereports-42	14	8	of	of	ADP
eyereports-42	14	9	intravitreal	intravitreal	ADJ
eyereports-42	14	10	drug	drug	NOUN
eyereports-42	14	11	injections	injection	NOUN
eyereports-42	14	12	followed	follow	VERB
eyereports-42	14	13	several	several	ADJ
eyereports-42	14	14	days	day	NOUN
eyereports-42	14	15	to	to	ADP
eyereports-42	14	16	weeks	week	NOUN
eyereports-42	14	17	later	later	ADV
eyereports-42	14	18	by	by	ADP
eyereports-42	14	19	sampling	sample	VERB
eyereports-42	14	20	of	of	ADP
eyereports-42	14	21	the	the	DET
eyereports-42	14	22	vitreous	vitreous	ADJ
eyereports-42	14	23	or	or	CCONJ
eyereports-42	14	24	aqueous	aqueous	ADJ
eyereports-42	14	25	during	during	ADP
eyereports-42	14	26	a	a	DET
eyereports-42	14	27	surgical	surgical	ADJ
eyereports-42	14	28	procedure	procedure	NOUN
eyereports-42	14	29	.	.	PUNCT
eyereports-42	15	1	for	for	ADP
eyereports-42	15	2	most	most	ADJ
eyereports-42	15	3	drugs	drug	NOUN
eyereports-42	15	4	,	,	PUNCT
eyereports-42	15	5	pharmacokinetic	pharmacokinetic	ADJ
eyereports-42	15	6	data	datum	NOUN
eyereports-42	15	7	in	in	ADP
eyereports-42	15	8	at	at	ADV
eyereports-42	15	9	least	least	ADV
eyereports-42	15	10	1	1	NUM
eyereports-42	15	11	animal	animal	NOUN
eyereports-42	15	12	model	model	NOUN
eyereports-42	15	13	has	have	AUX
eyereports-42	15	14	been	be	AUX
eyereports-42	15	15	determined	determine	VERB
eyereports-42	15	16	and	and	CCONJ
eyereports-42	15	17	some	some	PRON
eyereports-42	15	18	,	,	PUNCT
eyereports-42	15	19	such	such	ADJ
eyereports-42	15	20	as	as	ADP
eyereports-42	15	21	ranibizu	ranibizu	PROPN
eyereports-42	15	22	mab	mab	PROPN
eyereports-42	15	23	,	,	PUNCT
eyereports-42	15	24	receive	receive	VERB
eyereports-42	15	25	regulatory	regulatory	ADJ
eyereports-42	15	26	approval	approval	NOUN
eyereports-42	15	27	without	without	ADP
eyereports-42	15	28	human	human	ADJ
eyereports-42	15	29	pharmacokinetic	pharmacokinetic	NOUN
eyereports-42	15	30	studies.3,4	studies.3,4	ADJ
eyereports-42	15	31	the	the	DET
eyereports-42	15	32	goal	goal	NOUN
eyereports-42	15	33	of	of	ADP
eyereports-42	15	34	this	this	DET
eyereports-42	15	35	study	study	NOUN
eyereports-42	15	36	is	be	AUX
eyereports-42	15	37	to	to	PART
eyereports-42	15	38	estimate	estimate	VERB
eyereports-42	15	39	the	the	PRON
eyereports-42	15	40	as	as	ADV
eyereports-42	15	41	yet	yet	ADV
eyereports-42	15	42	undetermined	undetermined	ADJ
eyereports-42	15	43	intravitreal	intravitreal	ADJ
eyereports-42	15	44	half	half	ADJ
eyereports-42	15	45	-	-	PUNCT
eyereports-42	15	46	lives	life	NOUN
eyereports-42	15	47	of	of	ADP
eyereports-42	15	48	ranibizumab	ranibizumab	NOUN
eyereports-42	15	49	and	and	CCONJ
eyereports-42	15	50	the	the	DET
eyereports-42	15	51	vte	vte	NOUN
eyereports-42	15	52	in	in	ADP
eyereports-42	15	53	humans	human	NOUN
eyereports-42	15	54	by	by	ADP
eyereports-42	15	55	using	use	VERB
eyereports-42	15	56	experimental	experimental	ADJ
eyereports-42	15	57	animal	animal	NOUN
eyereports-42	15	58	and	and	CCONJ
eyereports-42	15	59	human	human	ADJ
eyereports-42	15	60	data	datum	NOUN
eyereports-42	15	61	combined	combine	VERB
eyereports-42	15	62	with	with	ADP
eyereports-42	15	63	a	a	DET
eyereports-42	15	64	previously	previously	ADV
eyereports-42	15	65	published	publish	VERB
eyereports-42	15	66	mathematical	mathematical	ADJ
eyereports-42	15	67	model.5	model.5	NOUN
eyereports-42	15	68	materials	material	NOUN
eyereports-42	15	69	and	and	CCONJ
eyereports-42	15	70	methods	method	NOUN
eyereports-42	15	71	a	a	DET
eyereports-42	15	72	medline	medline	NOUN
eyereports-42	15	73	search	search	NOUN
eyereports-42	15	74	for	for	ADP
eyereports-42	15	75	studies	study	NOUN
eyereports-42	15	76	reporting	report	VERB
eyereports-42	15	77	pharmacokinetic	pharmacokinetic	ADJ
eyereports-42	15	78	data	datum	NOUN
eyereports-42	15	79	on	on	ADP
eyereports-42	15	80	ranibizumab	ranibizumab	NOUN
eyereports-42	15	81	,	,	PUNCT
eyereports-42	15	82	bevacizumab	bevacizumab	PROPN
eyereports-42	15	83	,	,	PUNCT
eyereports-42	15	84	the	the	DET
eyereports-42	15	85	vte	vte	NOUN
eyereports-42	15	86	and	and	CCONJ
eyereports-42	15	87	similar	similar	ADJ
eyereports-42	15	88	macromolecules	macromolecule	NOUN
eyereports-42	15	89	in	in	ADP
eyereports-42	15	90	both	both	DET
eyereports-42	15	91	animals	animal	NOUN
eyereports-42	15	92	and	and	CCONJ
eyereports-42	15	93	humans	human	NOUN
eyereports-42	15	94	was	be	AUX
eyereports-42	15	95	performed	perform	VERB
eyereports-42	15	96	.	.	PUNCT
eyereports-42	16	1	unique	unique	ADJ
eyereports-42	16	2	animal	animal	NOUN
eyereports-42	16	3	models	model	NOUN
eyereports-42	16	4	rabbit	rabbit	NOUN
eyereports-42	16	5	and	and	CCONJ
eyereports-42	16	6	monkey	monkey	NOUN
eyereports-42	16	7	that	that	PRON
eyereports-42	16	8	tested	test	VERB
eyereports-42	16	9	both	both	DET
eyereports-42	16	10	ranibizumab	ranibizumab	NOUN
eyereports-42	16	11	and	and	CCONJ
eyereports-42	16	12	bevacizumab	bevacizumab	NOUN
eyereports-42	16	13	or	or	CCONJ
eyereports-42	16	14	structurally	structurally	ADV
eyereports-42	16	15	similar	similar	ADJ
eyereports-42	16	16	molecules	molecule	NOUN
eyereports-42	16	17	were	be	AUX
eyereports-42	16	18	identified.6	identified.6	ADJ
eyereports-42	16	19	-	-	PUNCT
eyereports-42	16	20	8	8	NUM
eyereports-42	16	21	the	the	DET
eyereports-42	16	22	intravitreal	intravitreal	ADJ
eyereports-42	16	23	half	half	ADJ
eyereports-42	16	24	-	-	PUNCT
eyereports-42	16	25	life	life	NOUN
eyereports-42	16	26	of	of	ADP
eyereports-42	16	27	bevacizumab	bevacizumab	NOUN
eyereports-42	16	28	in	in	ADP
eyereports-42	16	29	humans	human	NOUN
eyereports-42	16	30	was	be	AUX
eyereports-42	16	31	calculated	calculate	VERB
eyereports-42	16	32	by	by	ADP
eyereports-42	16	33	averaging	average	VERB
eyereports-42	16	34	values	value	NOUN
eyereports-42	16	35	from	from	ADP
eyereports-42	16	36	published	publish	VERB
eyereports-42	16	37	studies.9	studies.9	NOUN
eyereports-42	16	38	-	-	PUNCT
eyereports-42	16	39	10	10	NUM
eyereports-42	16	40	a	a	DET
eyereports-42	16	41	previously	previously	ADV
eyereports-42	16	42	published	publish	VERB
eyereports-42	16	43	mathematical	mathematical	ADJ
eyereports-42	16	44	model	model	NOUN
eyereports-42	16	45	that	that	PRON
eyereports-42	16	46	calculated	calculate	VERB
eyereports-42	16	47	intravitreal	intravitreal	ADJ
eyereports-42	16	48	drug	drug	NOUN
eyereports-42	16	49	half	half	ADJ
eyereports-42	16	50	-	-	PUNCT
eyereports-42	16	51	lives	life	NOUN
eyereports-42	16	52	in	in	ADP
eyereports-42	16	53	rabbits	rabbit	NOUN
eyereports-42	16	54	was	be	AUX
eyereports-42	16	55	employed.5	employed.5	PROPN
eyereports-42	16	56	the	the	DET
eyereports-42	16	57	model	model	NOUN
eyereports-42	16	58	predicts	predict	VERB
eyereports-42	16	59	the	the	DET
eyereports-42	16	60	half	half	ADJ
eyereports-42	16	61	-	-	PUNCT
eyereports-42	16	62	life	life	NOUN
eyereports-42	16	63	of	of	ADP
eyereports-42	16	64	a	a	DET
eyereports-42	16	65	drug	drug	NOUN
eyereports-42	16	66	according	accord	VERB
eyereports-42	16	67	to	to	ADP
eyereports-42	16	68	the	the	DET
eyereports-42	16	69	following	follow	VERB
eyereports-42	16	70	equation	equation	NOUN
eyereports-42	16	71	:	:	PUNCT
eyereports-42	16	72	log	log	VERB
eyereports-42	16	73	t1/2	t1/2	NOUN
eyereports-42	16	74	=	=	PUNCT
eyereports-42	16	75	-0.32	-0.32	VERB
eyereports-42	16	76	+	+	NOUN
eyereports-42	16	77	0.432	0.432	NUM
eyereports-42	16	78	*	*	NOUN
eyereports-42	16	79	(	(	PUNCT
eyereports-42	16	80	log	log	VERB
eyereports-42	16	81	mw)-0.157	mw)-0.157	PROPN
eyereports-42	16	82	*	*	PUNCT
eyereports-42	16	83	(	(	PUNCT
eyereports-42	16	84	log	log	VERB
eyereports-42	16	85	p)+0.003	p)+0.003	PROPN
eyereports-42	16	86	*	*	PUNCT
eyereports-42	16	87	(	(	PUNCT
eyereports-42	16	88	dose	dose	NOUN
eyereports-42	16	89	/	/	SYM
eyereports-42	16	90	solubility	solubility	NOUN
eyereports-42	16	91	)	)	PUNCT
eyereports-42	16	92	at	at	ADP
eyereports-42	16	93	ph	ph	NOUN
eyereports-42	16	94	7.4	7.4	NUM
eyereports-42	16	95	where	where	SCONJ
eyereports-42	16	96	:	:	PUNCT
eyereports-42	16	97	t1/2	t1/2	NOUN
eyereports-42	16	98	is	be	AUX
eyereports-42	16	99	the	the	DET
eyereports-42	16	100	half	half	ADJ
eyereports-42	16	101	-	-	PUNCT
eyereports-42	16	102	life	life	NOUN
eyereports-42	16	103	of	of	ADP
eyereports-42	16	104	the	the	DET
eyereports-42	16	105	compound	compound	NOUN
eyereports-42	16	106	.	.	PUNCT
eyereports-42	17	1	mw	mw	PROPN
eyereports-42	17	2	is	be	AUX
eyereports-42	17	3	the	the	DET
eyereports-42	17	4	molecular	molecular	ADJ
eyereports-42	17	5	weight	weight	NOUN
eyereports-42	17	6	of	of	ADP
eyereports-42	17	7	the	the	DET
eyereports-42	17	8	compound	compound	NOUN
eyereports-42	17	9	.	.	PUNCT
eyereports-42	18	1	log	log	PROPN
eyereports-42	18	2	p	p	NOUN
eyereports-42	18	3	is	be	AUX
eyereports-42	18	4	the	the	DET
eyereports-42	18	5	logarithm	logarithm	NOUN
eyereports-42	18	6	of	of	ADP
eyereports-42	18	7	p	p	PRON
eyereports-42	18	8	,	,	PUNCT
eyereports-42	18	9	the	the	DET
eyereports-42	18	10	partition	partition	NOUN
eyereports-42	18	11	coefficient	coefficient	NOUN
eyereports-42	18	12	or	or	CCONJ
eyereports-42	18	13	the	the	DET
eyereports-42	18	14	ratio	ratio	NOUN
eyereports-42	18	15	of	of	ADP
eyereports-42	18	16	the	the	DET
eyereports-42	18	17	concentrations	concentration	NOUN
eyereports-42	18	18	of	of	ADP
eyereports-42	18	19	an	an	DET
eyereports-42	18	20	un	un	ADJ
eyereports-42	18	21	-	-	ADJ
eyereports-42	18	22	ionized	ionized	ADJ
eyereports-42	18	23	compound	compound	NOUN
eyereports-42	18	24	in	in	ADP
eyereports-42	18	25	two	two	NUM
eyereports-42	18	26	immiscible	immiscible	ADJ
eyereports-42	18	27	phases	phase	NOUN
eyereports-42	18	28	at	at	ADP
eyereports-42	18	29	equilibrium	equilibrium	NOUN
eyereports-42	18	30	.	.	PUNCT
eyereports-42	19	1	as	as	ADP
eyereports-42	19	2	such	such	ADJ
eyereports-42	19	3	,	,	PUNCT
eyereports-42	19	4	log	log	PROPN
eyereports-42	19	5	p	p	NOUN
eyereports-42	19	6	is	be	AUX
eyereports-42	19	7	the	the	DET
eyereports-42	19	8	lipophilicity	lipophilicity	NOUN
eyereports-42	19	9	of	of	ADP
eyereports-42	19	10	the	the	DET
eyereports-42	19	11	compound	compound	NOUN
eyereports-42	19	12	and	and	CCONJ
eyereports-42	19	13	p=-0.51	p=-0.51	NOUN
eyereports-42	19	14	for	for	ADP
eyereports-42	19	15	macromolecules	macromolecule	NOUN
eyereports-42	19	16	.	.	PUNCT
eyereports-42	20	1	the	the	DET
eyereports-42	20	2	ratio	ratio	NOUN
eyereports-42	20	3	of	of	ADP
eyereports-42	20	4	dose	dose	NOUN
eyereports-42	20	5	/	/	SYM
eyereports-42	20	6	solubility	solubility	NOUN
eyereports-42	20	7	is	be	AUX
eyereports-42	20	8	assumed	assume	VERB
eyereports-42	20	9	to	to	PART
eyereports-42	20	10	be	be	AUX
eyereports-42	20	11	1	1	NUM
eyereports-42	20	12	for	for	ADP
eyereports-42	20	13	this	this	DET
eyereports-42	20	14	data	datum	NOUN
eyereports-42	20	15	set	set	VERB
eyereports-42	20	16	.	.	PUNCT
eyereports-42	21	1	to	to	PART
eyereports-42	21	2	test	test	VERB
eyereports-42	21	3	the	the	DET
eyereports-42	21	4	validity	validity	NOUN
eyereports-42	21	5	of	of	ADP
eyereports-42	21	6	the	the	DET
eyereports-42	21	7	model	model	NOUN
eyereports-42	21	8	,	,	PUNCT
eyereports-42	21	9	the	the	DET
eyereports-42	21	10	halflives	halflive	NOUN
eyereports-42	21	11	of	of	ADP
eyereports-42	21	12	ranibizumab	ranibizumab	NOUN
eyereports-42	21	13	and	and	CCONJ
eyereports-42	21	14	bevacizumab	bevacizumab	NOUN
eyereports-42	21	15	were	be	AUX
eyereports-42	21	16	calculated	calculate	VERB
eyereports-42	21	17	.	.	PUNCT
eyereports-42	22	1	the	the	DET
eyereports-42	22	2	slope	slope	NOUN
eyereports-42	22	3	coefficient	coefficient	NOUN
eyereports-42	22	4	(	(	PUNCT
eyereports-42	22	5	0.432	0.432	NUM
eyereports-42	22	6	)	)	PUNCT
eyereports-42	22	7	was	be	AUX
eyereports-42	22	8	changed	change	VERB
eyereports-42	22	9	slightly	slightly	ADV
eyereports-42	22	10	to	to	PART
eyereports-42	22	11	set	set	VERB
eyereports-42	22	12	the	the	DET
eyereports-42	22	13	half	half	ADJ
eyereports-42	22	14	-	-	PUNCT
eyereports-42	22	15	life	life	NOUN
eyereports-42	22	16	of	of	ADP
eyereports-42	22	17	bevacizumab	bevacizumab	NOUN
eyereports-42	22	18	equal	equal	ADJ
eyereports-42	22	19	to	to	ADP
eyereports-42	22	20	the	the	DET
eyereports-42	22	21	published	publish	VERB
eyereports-42	22	22	value	value	NOUN
eyereports-42	22	23	,	,	PUNCT
eyereports-42	22	24	the	the	DET
eyereports-42	22	25	expected	expect	VERB
eyereports-42	22	26	half	half	ADJ
eyereports-42	22	27	-	-	PUNCT
eyereports-42	22	28	life	life	NOUN
eyereports-42	22	29	of	of	ADP
eyereports-42	22	30	ranibizumab	ranibizumab	NOUN
eyereports-42	22	31	was	be	AUX
eyereports-42	22	32	re	re	VERB
eyereports-42	22	33	-	-	VERB
eyereports-42	22	34	calculated	calculate	VERB
eyereports-42	22	35	,	,	PUNCT
eyereports-42	22	36	and	and	CCONJ
eyereports-42	22	37	the	the	DET
eyereports-42	22	38	deviation	deviation	NOUN
eyereports-42	22	39	,	,	PUNCT
eyereports-42	22	40	as	as	ADP
eyereports-42	22	41	a	a	DET
eyereports-42	22	42	percentage	percentage	NOUN
eyereports-42	22	43	from	from	ADP
eyereports-42	22	44	the	the	DET
eyereports-42	22	45	published	publish	VERB
eyereports-42	22	46	value	value	NOUN
eyereports-42	22	47	,	,	PUNCT
eyereports-42	22	48	was	be	AUX
eyereports-42	22	49	calculated	calculate	VERB
eyereports-42	22	50	.	.	PUNCT
eyereports-42	23	1	the	the	DET
eyereports-42	23	2	mutability	mutability	NOUN
eyereports-42	23	3	of	of	ADP
eyereports-42	23	4	the	the	DET
eyereports-42	23	5	model	model	NOUN
eyereports-42	23	6	to	to	PART
eyereports-42	23	7	monkey	monkey	NOUN
eyereports-42	23	8	eyes	eye	NOUN
eyereports-42	23	9	was	be	AUX
eyereports-42	23	10	then	then	ADV
eyereports-42	23	11	tested	test	VERB
eyereports-42	23	12	.	.	PUNCT
eyereports-42	24	1	the	the	DET
eyereports-42	24	2	slope	slope	NOUN
eyereports-42	24	3	coefficient	coefficient	NOUN
eyereports-42	24	4	was	be	AUX
eyereports-42	24	5	changed	change	VERB
eyereports-42	24	6	to	to	PART
eyereports-42	24	7	set	set	VERB
eyereports-42	24	8	the	the	DET
eyereports-42	24	9	bevacizumab	bevacizumab	NOUN
eyereports-42	24	10	half	half	ADJ
eyereports-42	24	11	-	-	PUNCT
eyereports-42	24	12	life	life	NOUN
eyereports-42	24	13	equal	equal	ADJ
eyereports-42	24	14	to	to	ADP
eyereports-42	24	15	the	the	DET
eyereports-42	24	16	published	publish	VERB
eyereports-42	24	17	value	value	NOUN
eyereports-42	24	18	,	,	PUNCT
eyereports-42	24	19	the	the	DET
eyereports-42	24	20	expected	expect	VERB
eyereports-42	24	21	ranibizumab	ranibizumab	NOUN
eyereports-42	24	22	halflife	halflife	NOUN
eyereports-42	24	23	was	be	AUX
eyereports-42	24	24	calculated	calculate	VERB
eyereports-42	24	25	,	,	PUNCT
eyereports-42	24	26	and	and	CCONJ
eyereports-42	24	27	the	the	DET
eyereports-42	24	28	deviation	deviation	NOUN
eyereports-42	24	29	,	,	PUNCT
eyereports-42	24	30	as	as	ADP
eyereports-42	24	31	a	a	DET
eyereports-42	24	32	percentage	percentage	NOUN
eyereports-42	24	33	from	from	ADP
eyereports-42	24	34	the	the	DET
eyereports-42	24	35	published	publish	VERB
eyereports-42	24	36	value	value	NOUN
eyereports-42	24	37	,	,	PUNCT
eyereports-42	24	38	was	be	AUX
eyereports-42	24	39	calculated	calculate	VERB
eyereports-42	24	40	.	.	PUNCT
eyereports-42	25	1	finally	finally	ADV
eyereports-42	25	2	the	the	DET
eyereports-42	25	3	model	model	NOUN
eyereports-42	25	4	was	be	AUX
eyereports-42	25	5	used	use	VERB
eyereports-42	25	6	to	to	PART
eyereports-42	25	7	calculate	calculate	VERB
eyereports-42	25	8	the	the	DET
eyereports-42	25	9	drug	drug	NOUN
eyereports-42	25	10	half	half	ADJ
eyereports-42	25	11	-	-	PUNCT
eyereports-42	25	12	lives	life	NOUN
eyereports-42	25	13	in	in	ADP
eyereports-42	25	14	human	human	ADJ
eyereports-42	25	15	eyes	eye	NOUN
eyereports-42	25	16	.	.	PUNCT
eyereports-42	26	1	the	the	DET
eyereports-42	26	2	slope	slope	NOUN
eyereports-42	26	3	coefficient	coefficient	NOUN
eyereports-42	26	4	was	be	AUX
eyereports-42	26	5	changed	change	VERB
eyereports-42	26	6	to	to	PART
eyereports-42	26	7	set	set	VERB
eyereports-42	26	8	the	the	DET
eyereports-42	26	9	bevacizumab	bevacizumab	NOUN
eyereports-42	26	10	half	half	ADJ
eyereports-42	26	11	-	-	PUNCT
eyereports-42	26	12	life	life	NOUN
eyereports-42	26	13	equal	equal	ADJ
eyereports-42	26	14	to	to	ADP
eyereports-42	26	15	the	the	DET
eyereports-42	26	16	average	average	NOUN
eyereports-42	26	17	of	of	ADP
eyereports-42	26	18	the	the	DET
eyereports-42	26	19	published	publish	VERB
eyereports-42	26	20	values	value	NOUN
eyereports-42	26	21	(	(	PUNCT
eyereports-42	26	22	8.25	8.25	NUM
eyereports-42	26	23	days	day	NOUN
eyereports-42	26	24	)	)	PUNCT
eyereports-42	26	25	and	and	CCONJ
eyereports-42	26	26	the	the	DET
eyereports-42	26	27	half	half	ADJ
eyereports-42	26	28	-	-	PUNCT
eyereports-42	26	29	lives	life	NOUN
eyereports-42	26	30	of	of	ADP
eyereports-42	26	31	ranibizumab	ranibizumab	NOUN
eyereports-42	26	32	(	(	PUNCT
eyereports-42	26	33	mw-48	mw-48	X
eyereports-42	26	34	kd	kd	NOUN
eyereports-42	26	35	)	)	PUNCT
eyereports-42	26	36	and	and	CCONJ
eyereports-42	26	37	the	the	DET
eyereports-42	26	38	vte	vte	NOUN
eyereports-42	26	39	(	(	PUNCT
eyereports-42	26	40	mw110kd	mw110kd	NOUN
eyereports-42	26	41	)	)	PUNCT
eyereports-42	26	42	were	be	AUX
eyereports-42	26	43	calculated	calculate	VERB
eyereports-42	26	44	.	.	PUNCT
eyereports-42	27	1	to	to	PART
eyereports-42	27	2	determine	determine	VERB
eyereports-42	27	3	the	the	DET
eyereports-42	27	4	possible	possible	ADJ
eyereports-42	27	5	relationship	relationship	NOUN
eyereports-42	27	6	between	between	ADP
eyereports-42	27	7	the	the	DET
eyereports-42	27	8	size	size	NOUN
eyereports-42	27	9	of	of	ADP
eyereports-42	27	10	the	the	DET
eyereports-42	27	11	eye	eye	NOUN
eyereports-42	27	12	and	and	CCONJ
eyereports-42	27	13	the	the	DET
eyereports-42	27	14	mutability	mutability	NOUN
eyereports-42	27	15	of	of	ADP
eyereports-42	27	16	the	the	DET
eyereports-42	27	17	equation	equation	NOUN
eyereports-42	27	18	,	,	PUNCT
eyereports-42	27	19	the	the	DET
eyereports-42	27	20	slope	slope	NOUN
eyereports-42	27	21	coefficients	coefficient	NOUN
eyereports-42	27	22	were	be	AUX
eyereports-42	27	23	graphed	graph	VERB
eyereports-42	27	24	against	against	ADP
eyereports-42	27	25	the	the	DET
eyereports-42	27	26	intravitreal	intravitreal	ADJ
eyereports-42	27	27	volumes	volume	NOUN
eyereports-42	27	28	and	and	CCONJ
eyereports-42	27	29	subjected	subject	VERB
eyereports-42	27	30	to	to	ADP
eyereports-42	27	31	a	a	DET
eyereports-42	27	32	regression	regression	NOUN
eyereports-42	27	33	analysis	analysis	NOUN
eyereports-42	27	34	.	.	PUNCT
eyereports-42	28	1	results	result	NOUN
eyereports-42	28	2	based	base	VERB
eyereports-42	28	3	upon	upon	SCONJ
eyereports-42	28	4	a	a	DET
eyereports-42	28	5	review	review	NOUN
eyereports-42	28	6	of	of	ADP
eyereports-42	28	7	the	the	DET
eyereports-42	28	8	literature	literature	NOUN
eyereports-42	28	9	(	(	PUNCT
eyereports-42	28	10	table	table	NOUN
eyereports-42	28	11	1),3,4,6	1),3,4,6	PROPN
eyereports-42	28	12	-	-	SYM
eyereports-42	28	13	14	14	NUM
eyereports-42	28	14	the	the	DET
eyereports-42	28	15	following	follow	VERB
eyereports-42	28	16	animal	animal	NOUN
eyereports-42	28	17	models	model	NOUN
eyereports-42	28	18	were	be	AUX
eyereports-42	28	19	selected	select	VERB
eyereports-42	28	20	against	against	ADP
eyereports-42	28	21	which	which	PRON
eyereports-42	28	22	to	to	PART
eyereports-42	28	23	test	test	VERB
eyereports-42	28	24	the	the	DET
eyereports-42	28	25	validity	validity	NOUN
eyereports-42	28	26	and	and	CCONJ
eyereports-42	28	27	mutability	mutability	NOUN
eyereports-42	28	28	of	of	ADP
eyereports-42	28	29	the	the	DET
eyereports-42	28	30	modified	modified	ADJ
eyereports-42	28	31	half	half	ADJ
eyereports-42	28	32	-	-	PUNCT
eyereports-42	28	33	life	life	NOUN
eyereports-42	28	34	equation	equation	NOUN
eyereports-42	28	35	:	:	PUNCT
eyereports-42	28	36	i	i	NOUN
eyereports-42	28	37	)	)	PUNCT
eyereports-42	28	38	for	for	ADP
eyereports-42	28	39	rabbits	rabbit	NOUN
eyereports-42	28	40	,	,	PUNCT
eyereports-42	29	1	bakri	bakri	PROPN
eyereports-42	29	2	et	et	PROPN
eyereports-42	29	3	al	al	PROPN
eyereports-42	29	4	.	.	PROPN
eyereports-42	29	5	determined	determine	VERB
eyereports-42	29	6	ranibizumab	ranibizumab	NOUN
eyereports-42	29	7	and	and	CCONJ
eyereports-42	29	8	bevacizumab	bevacizumab	NOUN
eyereports-42	29	9	half	half	ADJ
eyereports-42	29	10	-	-	PUNCT
eyereports-42	29	11	lives	life	NOUN
eyereports-42	29	12	of	of	ADP
eyereports-42	29	13	2.88	2.88	NUM
eyereports-42	29	14	days	day	NOUN
eyereports-42	29	15	and	and	CCONJ
eyereports-42	29	16	4.32	4.32	NUM
eyereports-42	29	17	days	day	NOUN
eyereports-42	29	18	respectively;7,8	respectively;7,8	PROPN
eyereports-42	29	19	ii	ii	NOUN
eyereports-42	29	20	)	)	PUNCT
eyereports-42	29	21	for	for	ADP
eyereports-42	29	22	monkeys	monkey	NOUN
eyereports-42	29	23	,	,	PUNCT
eyereports-42	29	24	mordenti	mordenti	PROPN
eyereports-42	29	25	et	et	PROPN
eyereports-42	29	26	al	al	PROPN
eyereports-42	29	27	.	.	PROPN
eyereports-42	29	28	determined	determine	VERB
eyereports-42	29	29	fab	fab	NOUN
eyereports-42	29	30	and	and	CCONJ
eyereports-42	29	31	her2	her2	PROPN
eyereports-42	29	32	(	(	PUNCT
eyereports-42	29	33	macromolecules	macromolecule	NOUN
eyereports-42	29	34	structurally	structurally	ADV
eyereports-42	29	35	similar	similar	ADJ
eyereports-42	29	36	to	to	ADP
eyereports-42	29	37	ranibizumab	ranibizumab	NOUN
eyereports-42	29	38	and	and	CCONJ
eyereports-42	29	39	bevacizumab	bevacizumab	NOUN
eyereports-42	29	40	,	,	PUNCT
eyereports-42	29	41	respectively	respectively	ADV
eyereports-42	29	42	)	)	PUNCT
eyereports-42	29	43	half	half	ADJ
eyereports-42	29	44	-	-	PUNCT
eyereports-42	29	45	lives	life	NOUN
eyereports-42	29	46	of	of	ADP
eyereports-42	29	47	3.2	3.2	NUM
eyereports-42	29	48	days	day	NOUN
eyereports-42	29	49	and	and	CCONJ
eyereports-42	29	50	5.6	5.6	NUM
eyereports-42	29	51	days	day	NOUN
eyereports-42	29	52	respectively.6	respectively.6	NOUN
eyereports-42	29	53	using	use	VERB
eyereports-42	29	54	the	the	DET
eyereports-42	29	55	published	publish	VERB
eyereports-42	29	56	half	half	ADJ
eyereports-42	29	57	-	-	PUNCT
eyereports-42	29	58	life	life	NOUN
eyereports-42	29	59	equation	equation	NOUN
eyereports-42	29	60	,	,	PUNCT
eyereports-42	29	61	the	the	DET
eyereports-42	29	62	initially	initially	ADV
eyereports-42	29	63	calculated	calculate	VERB
eyereports-42	29	64	half	half	ADJ
eyereports-42	29	65	-	-	PUNCT
eyereports-42	29	66	lives	life	NOUN
eyereports-42	29	67	of	of	ADP
eyereports-42	29	68	ranibizumab	ranibizumab	NOUN
eyereports-42	29	69	and	and	CCONJ
eyereports-42	29	70	bevacizumab	bevacizumab	NOUN
eyereports-42	29	71	in	in	ADP
eyereports-42	29	72	rabbit	rabbit	NOUN
eyereports-42	29	73	eyes	eye	NOUN
eyereports-42	29	74	were	be	AUX
eyereports-42	29	75	2.54	2.54	NUM
eyereports-42	29	76	days	day	NOUN
eyereports-42	29	77	and	and	CCONJ
eyereports-42	29	78	4.17	4.17	NUM
eyereports-42	29	79	days	day	NOUN
eyereports-42	29	80	.	.	PUNCT
eyereports-42	30	1	the	the	DET
eyereports-42	30	2	slope	slope	NOUN
eyereports-42	30	3	coefficient	coefficient	NOUN
eyereports-42	30	4	was	be	AUX
eyereports-42	30	5	increased	increase	VERB
eyereports-42	30	6	from	from	ADP
eyereports-42	30	7	0.43200	0.43200	NUM
eyereports-42	30	8	to	to	ADP
eyereports-42	30	9	0.43564	0.43564	NUM
eyereports-42	30	10	to	to	PART
eyereports-42	30	11	set	set	VERB
eyereports-42	30	12	the	the	DET
eyereports-42	30	13	output	output	NOUN
eyereports-42	30	14	for	for	ADP
eyereports-42	30	15	bevacizumab	bevacizumab	NOUN
eyereports-42	30	16	to	to	PART
eyereports-42	30	17	equal	equal	VERB
eyereports-42	30	18	4.32	4.32	NUM
eyereports-42	30	19	days	day	NOUN
eyereports-42	30	20	.	.	PUNCT
eyereports-42	31	1	the	the	DET
eyereports-42	31	2	re	re	VERB
eyereports-42	31	3	-	-	ADJ
eyereports-42	31	4	calculated	calculate	VERB
eyereports-42	31	5	half	half	ADJ
eyereports-42	31	6	-	-	PUNCT
eyereports-42	31	7	life	life	NOUN
eyereports-42	31	8	of	of	ADP
eyereports-42	31	9	ranibizumab	ranibizumab	NOUN
eyereports-42	31	10	was	be	AUX
eyereports-42	31	11	2.64	2.64	NUM
eyereports-42	31	12	days	day	NOUN
eyereports-42	31	13	,	,	PUNCT
eyereports-42	31	14	only	only	ADV
eyereports-42	31	15	8.3	8.3	NUM
eyereports-42	31	16	%	%	NOUN
eyereports-42	31	17	shorter	short	ADJ
eyereports-42	31	18	than	than	ADP
eyereports-42	31	19	the	the	DET
eyereports-42	31	20	experimental	experimental	ADJ
eyereports-42	31	21	eye	eye	NOUN
eyereports-42	31	22	reports	report	VERB
eyereports-42	31	23	2011	2011	NUM
eyereports-42	31	24	;	;	PUNCT
eyereports-42	31	25	volume	volume	NOUN
eyereports-42	31	26	1	1	NUM
eyereports-42	31	27	:	:	PUNCT
eyereports-42	31	28	e5	e5	PROPN
eyereports-42	31	29	correspondence	correspondence	NOUN
eyereports-42	31	30	:	:	PUNCT
eyereports-42	31	31	michael	michael	PROPN
eyereports-42	31	32	w.	w.	PROPN
eyereports-42	31	33	stewart	stewart	PROPN
eyereports-42	31	34	,	,	PUNCT
eyereports-42	31	35	4500	4500	NUM
eyereports-42	31	36	san	san	PROPN
eyereports-42	31	37	pablo	pablo	PROPN
eyereports-42	31	38	rd	rd	PROPN
eyereports-42	31	39	.	.	PROPN
eyereports-42	31	40	,	,	PUNCT
eyereports-42	31	41	jacksonville	jacksonville	PROPN
eyereports-42	31	42	,	,	PUNCT
eyereports-42	31	43	fl	fl	PROPN
eyereports-42	31	44	32224	32224	NUM
eyereports-42	31	45	,	,	PUNCT
eyereports-42	31	46	usa	usa	PROPN
eyereports-42	32	1	.	.	PROPN
eyereports-42	32	2	tel	tel	PROPN
eyereports-42	32	3	.	.	PUNCT
eyereports-42	33	1	+1.904.953.2232	+1.904.953.2232	PROPN
eyereports-42	33	2	fax	fax	NOUN
eyereports-42	33	3	:	:	PUNCT
eyereports-42	33	4	+1.904.953.7040	+1.904.953.7040	NUM
eyereports-42	33	5	.	.	PUNCT
eyereports-42	34	1	e	e	X
eyereports-42	34	2	-	-	NOUN
eyereports-42	34	3	mail	mail	NOUN
eyereports-42	34	4	:	:	PUNCT
eyereports-42	34	5	stewart.michael@mayo.edu	stewart.michael@mayo.edu	VERB
eyereports-42	34	6	key	key	ADJ
eyereports-42	34	7	words	word	NOUN
eyereports-42	34	8	:	:	PUNCT
eyereports-42	34	9	age	age	NOUN
eyereports-42	34	10	-	-	PUNCT
eyereports-42	34	11	related	relate	VERB
eyereports-42	34	12	macular	macular	ADJ
eyereports-42	34	13	degeneration	degeneration	NOUN
eyereports-42	34	14	,	,	PUNCT
eyereports-42	34	15	ranibizumab	ranibizumab	NOUN
eyereports-42	34	16	,	,	PUNCT
eyereports-42	34	17	bevacizumab	bevacizumab	PROPN
eyereports-42	34	18	,	,	PUNCT
eyereports-42	34	19	vegf	vegf	PROPN
eyereports-42	34	20	trap	trap	PROPN
eyereports-42	34	21	,	,	PUNCT
eyereports-42	34	22	aflibercept	aflibercept	ADJ
eyereports-42	34	23	,	,	PUNCT
eyereports-42	34	24	half	half	ADJ
eyereports-42	34	25	-	-	PUNCT
eyereports-42	34	26	lives	life	NOUN
eyereports-42	34	27	,	,	PUNCT
eyereports-42	34	28	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	34	29	.	.	PUNCT
eyereports-42	35	1	received	receive	VERB
eyereports-42	35	2	for	for	ADP
eyereports-42	35	3	publication	publication	NOUN
eyereports-42	35	4	:	:	PUNCT
eyereports-42	35	5	11	11	NUM
eyereports-42	35	6	june	june	PROPN
eyereports-42	35	7	2011	2011	NUM
eyereports-42	35	8	.	.	PUNCT
eyereports-42	36	1	accepted	accept	VERB
eyereports-42	36	2	for	for	ADP
eyereports-42	36	3	publication	publication	NOUN
eyereports-42	36	4	:	:	PUNCT
eyereports-42	36	5	31	31	NUM
eyereports-42	36	6	july	july	PROPN
eyereports-42	36	7	2011	2011	NUM
eyereports-42	36	8	.	.	PUNCT
eyereports-42	37	1	this	this	DET
eyereports-42	37	2	work	work	NOUN
eyereports-42	37	3	is	be	AUX
eyereports-42	37	4	licensed	license	VERB
eyereports-42	37	5	under	under	ADP
eyereports-42	37	6	a	a	DET
eyereports-42	37	7	creative	creative	ADJ
eyereports-42	37	8	commons	common	NOUN
eyereports-42	37	9	attribution	attribution	NOUN
eyereports-42	37	10	noncommercial	noncommercial	ADJ
eyereports-42	37	11	3.0	3.0	NUM
eyereports-42	37	12	license	license	NOUN
eyereports-42	37	13	(	(	PUNCT
eyereports-42	37	14	cc	cc	VERB
eyereports-42	37	15	bync	bync	PROPN
eyereports-42	37	16	3.0	3.0	NUM
eyereports-42	37	17	)	)	PUNCT
eyereports-42	37	18	.	.	PUNCT
eyereports-42	38	1	©	©	PROPN
eyereports-42	38	2	copyright	copyright	PROPN
eyereports-42	38	3	m.w	m.w	PROPN
eyereports-42	38	4	.	.	PROPN
eyereports-42	38	5	stewart	stewart	PROPN
eyereports-42	38	6	,	,	PUNCT
eyereports-42	38	7	2011	2011	NUM
eyereports-42	38	8	licensee	licensee	NOUN
eyereports-42	38	9	pagepress	pagepress	NOUN
eyereports-42	38	10	,	,	PUNCT
eyereports-42	38	11	italy	italy	PROPN
eyereports-42	38	12	eye	eye	PROPN
eyereports-42	38	13	reports	report	VERB
eyereports-42	38	14	2011	2011	NUM
eyereports-42	38	15	;	;	PUNCT
eyereports-42	38	16	1	1	NUM
eyereports-42	38	17	:	:	PUNCT
eyereports-42	38	18	e5	e5	PROPN
eyereports-42	38	19	doi:10.4081	doi:10.4081	NOUN
eyereports-42	38	20	/	/	SYM
eyereports-42	38	21	eye.2011.e5	eye.2011.e5	VERB
eyereports-42	38	22	non	non	ADJ
eyereports-42	38	23	-co	-co	PROPN
eyereports-42	38	24	mmerc	mmerc	PROPN
eyereports-42	38	25	ial	ial	PROPN
eyereports-42	39	1	us	us	PROPN
eyereports-42	40	1	e	e	NOUN
eyereports-42	40	2	o	o	NOUN
eyereports-42	40	3	nly	nly	ADV
eyereports-42	40	4	[	[	X
eyereports-42	40	5	eye	eye	NOUN
eyereports-42	40	6	reports	report	VERB
eyereports-42	40	7	2011	2011	NUM
eyereports-42	40	8	;	;	PUNCT
eyereports-42	40	9	1	1	NUM
eyereports-42	40	10	:	:	PUNCT
eyereports-42	40	11	e5	e5	X
eyereports-42	40	12	]	]	X
eyereports-42	41	1	[	[	X
eyereports-42	41	2	page	page	NOUN
eyereports-42	41	3	13	13	NUM
eyereports-42	41	4	]	]	SYM
eyereports-42	41	5	value	value	NOUN
eyereports-42	41	6	(	(	PUNCT
eyereports-42	41	7	2.88	2.88	NUM
eyereports-42	41	8	days	day	NOUN
eyereports-42	41	9	)	)	PUNCT
eyereports-42	41	10	.	.	PUNCT
eyereports-42	42	1	to	to	PART
eyereports-42	42	2	establish	establish	VERB
eyereports-42	42	3	the	the	DET
eyereports-42	42	4	mutability	mutability	NOUN
eyereports-42	42	5	of	of	ADP
eyereports-42	42	6	the	the	DET
eyereports-42	42	7	half	half	ADJ
eyereports-42	42	8	-	-	PUNCT
eyereports-42	42	9	life	life	NOUN
eyereports-42	42	10	equation	equation	NOUN
eyereports-42	42	11	to	to	PART
eyereports-42	42	12	monkey	monkey	VERB
eyereports-42	42	13	eyes	eye	NOUN
eyereports-42	42	14	,	,	PUNCT
eyereports-42	42	15	the	the	DET
eyereports-42	42	16	slope	slope	NOUN
eyereports-42	42	17	coefficient	coefficient	NOUN
eyereports-42	42	18	was	be	AUX
eyereports-42	42	19	increased	increase	VERB
eyereports-42	42	20	to	to	ADP
eyereports-42	42	21	0.45720	0.45720	NUM
eyereports-42	42	22	to	to	PART
eyereports-42	42	23	set	set	VERB
eyereports-42	42	24	the	the	DET
eyereports-42	42	25	bevacizumab	bevacizumab	NOUN
eyereports-42	42	26	output	output	NOUN
eyereports-42	42	27	to	to	ADP
eyereports-42	42	28	5.6	5.6	NUM
eyereports-42	42	29	days	day	NOUN
eyereports-42	42	30	.	.	PUNCT
eyereports-42	43	1	the	the	DET
eyereports-42	43	2	calculated	calculated	ADJ
eyereports-42	43	3	half	half	ADJ
eyereports-42	43	4	-	-	PUNCT
eyereports-42	43	5	life	life	NOUN
eyereports-42	43	6	of	of	ADP
eyereports-42	43	7	ranibizumab	ranibizumab	NOUN
eyereports-42	43	8	was	be	AUX
eyereports-42	43	9	3.34	3.34	NUM
eyereports-42	43	10	days	day	NOUN
eyereports-42	43	11	,	,	PUNCT
eyereports-42	43	12	only	only	ADV
eyereports-42	43	13	4.2	4.2	NUM
eyereports-42	43	14	%	%	NOUN
eyereports-42	43	15	above	above	ADP
eyereports-42	43	16	the	the	DET
eyereports-42	43	17	experimental	experimental	ADJ
eyereports-42	43	18	value	value	NOUN
eyereports-42	43	19	(	(	PUNCT
eyereports-42	43	20	3.2	3.2	NUM
eyereports-42	43	21	days	day	NOUN
eyereports-42	43	22	)	)	PUNCT
eyereports-42	43	23	.	.	PUNCT
eyereports-42	44	1	to	to	PART
eyereports-42	44	2	calculate	calculate	VERB
eyereports-42	44	3	the	the	DET
eyereports-42	44	4	half	half	ADJ
eyereports-42	44	5	-	-	PUNCT
eyereports-42	44	6	lives	life	NOUN
eyereports-42	44	7	of	of	ADP
eyereports-42	44	8	ranibizumab	ranibizumab	NOUN
eyereports-42	44	9	and	and	CCONJ
eyereports-42	44	10	the	the	DET
eyereports-42	44	11	vte	vte	NOUN
eyereports-42	44	12	in	in	ADP
eyereports-42	44	13	human	human	ADJ
eyereports-42	44	14	eyes	eye	NOUN
eyereports-42	44	15	the	the	DET
eyereports-42	44	16	slope	slope	NOUN
eyereports-42	44	17	coefficient	coefficient	NOUN
eyereports-42	44	18	was	be	AUX
eyereports-42	44	19	changed	change	VERB
eyereports-42	44	20	a	a	DET
eyereports-42	44	21	third	third	ADJ
eyereports-42	44	22	time	time	NOUN
eyereports-42	44	23	.	.	PUNCT
eyereports-42	45	1	increasing	increase	VERB
eyereports-42	45	2	the	the	DET
eyereports-42	45	3	coefficient	coefficient	NOUN
eyereports-42	45	4	to	to	ADP
eyereports-42	45	5	0.49000	0.49000	NUM
eyereports-42	45	6	calculates	calculate	VERB
eyereports-42	45	7	the	the	DET
eyereports-42	45	8	bevacizumab	bevacizumab	NOUN
eyereports-42	45	9	half	half	ADJ
eyereports-42	45	10	-	-	PUNCT
eyereports-42	45	11	life	life	NOUN
eyereports-42	45	12	to	to	PART
eyereports-42	45	13	be	be	AUX
eyereports-42	45	14	8.25	8.25	NUM
eyereports-42	45	15	days	day	NOUN
eyereports-42	45	16	,	,	PUNCT
eyereports-42	45	17	the	the	DET
eyereports-42	45	18	average	average	ADJ
eyereports-42	45	19	value	value	NOUN
eyereports-42	45	20	reported	report	VERB
eyereports-42	45	21	in	in	ADP
eyereports-42	45	22	the	the	DET
eyereports-42	45	23	literature	literature	NOUN
eyereports-42	45	24	.	.	PUNCT
eyereports-42	46	1	by	by	ADP
eyereports-42	46	2	inputting	inputte	VERB
eyereports-42	46	3	the	the	DET
eyereports-42	46	4	molecular	molecular	ADJ
eyereports-42	46	5	weights	weight	NOUN
eyereports-42	46	6	of	of	ADP
eyereports-42	46	7	ranibizumab	ranibizumab	NOUN
eyereports-42	46	8	and	and	CCONJ
eyereports-42	46	9	the	the	DET
eyereports-42	46	10	vte	vte	NOUN
eyereports-42	46	11	,	,	PUNCT
eyereports-42	46	12	their	their	PRON
eyereports-42	46	13	half	half	ADJ
eyereports-42	46	14	-	-	PUNCT
eyereports-42	46	15	lives	life	NOUN
eyereports-42	46	16	are	be	AUX
eyereports-42	46	17	calculated	calculate	VERB
eyereports-42	46	18	to	to	PART
eyereports-42	46	19	be	be	AUX
eyereports-42	46	20	4.75	4.75	NUM
eyereports-42	46	21	days	day	NOUN
eyereports-42	46	22	and	and	CCONJ
eyereports-42	46	23	7.13	7.13	NUM
eyereports-42	46	24	days	day	NOUN
eyereports-42	46	25	.	.	PUNCT
eyereports-42	47	1	to	to	PART
eyereports-42	47	2	determine	determine	VERB
eyereports-42	47	3	a	a	DET
eyereports-42	47	4	possible	possible	ADJ
eyereports-42	47	5	relationship	relationship	NOUN
eyereports-42	47	6	between	between	ADP
eyereports-42	47	7	eye	eye	NOUN
eyereports-42	47	8	size	size	NOUN
eyereports-42	47	9	and	and	CCONJ
eyereports-42	47	10	mutability	mutability	NOUN
eyereports-42	47	11	of	of	ADP
eyereports-42	47	12	the	the	DET
eyereports-42	47	13	equation	equation	NOUN
eyereports-42	47	14	between	between	ADP
eyereports-42	47	15	species	specie	NOUN
eyereports-42	47	16	,	,	PUNCT
eyereports-42	47	17	the	the	DET
eyereports-42	47	18	3	3	NUM
eyereports-42	47	19	slope	slope	NOUN
eyereports-42	47	20	coefficients	coefficient	NOUN
eyereports-42	47	21	used	use	VERB
eyereports-42	47	22	in	in	ADP
eyereports-42	47	23	the	the	DET
eyereports-42	47	24	previous	previous	ADJ
eyereports-42	47	25	calculations	calculation	NOUN
eyereports-42	47	26	were	be	AUX
eyereports-42	47	27	graphed	graph	VERB
eyereports-42	47	28	against	against	ADP
eyereports-42	47	29	eye	eye	NOUN
eyereports-42	47	30	volumes	volume	NOUN
eyereports-42	47	31	(	(	PUNCT
eyereports-42	47	32	figure	figure	NOUN
eyereports-42	47	33	1	1	NUM
eyereports-42	47	34	)	)	PUNCT
eyereports-42	47	35	.	.	PUNCT
eyereports-42	48	1	a	a	DET
eyereports-42	48	2	linear	linear	ADJ
eyereports-42	48	3	relationship	relationship	NOUN
eyereports-42	48	4	with	with	ADP
eyereports-42	48	5	a	a	DET
eyereports-42	48	6	high	high	ADJ
eyereports-42	48	7	correlation	correlation	NOUN
eyereports-42	48	8	coefficient	coefficient	NOUN
eyereports-42	48	9	(	(	PUNCT
eyereports-42	48	10	r2	r2	PROPN
eyereports-42	48	11	=	=	SYM
eyereports-42	48	12	0.9956	0.9956	NUM
eyereports-42	48	13	)	)	PUNCT
eyereports-42	48	14	was	be	AUX
eyereports-42	48	15	determined	determine	VERB
eyereports-42	48	16	.	.	PUNCT
eyereports-42	49	1	discussion	discussion	NOUN
eyereports-42	49	2	accurate	accurate	ADJ
eyereports-42	49	3	intraocular	intraocular	ADJ
eyereports-42	49	4	drug	drug	NOUN
eyereports-42	49	5	half	half	ADJ
eyereports-42	49	6	-	-	PUNCT
eyereports-42	49	7	lives	life	NOUN
eyereports-42	49	8	allow	allow	VERB
eyereports-42	49	9	physicians	physician	NOUN
eyereports-42	49	10	to	to	PART
eyereports-42	49	11	create	create	VERB
eyereports-42	49	12	efficacy	efficacy	NOUN
eyereports-42	49	13	models	model	NOUN
eyereports-42	49	14	to	to	PART
eyereports-42	49	15	predict	predict	VERB
eyereports-42	49	16	the	the	DET
eyereports-42	49	17	results	result	NOUN
eyereports-42	49	18	of	of	ADP
eyereports-42	49	19	untested	untested	ADJ
eyereports-42	49	20	clinical	clinical	ADJ
eyereports-42	49	21	situations	situation	NOUN
eyereports-42	49	22	and	and	CCONJ
eyereports-42	49	23	to	to	PART
eyereports-42	49	24	more	more	ADV
eyereports-42	49	25	accurately	accurately	ADV
eyereports-42	49	26	predict	predict	VERB
eyereports-42	49	27	drug	drug	NOUN
eyereports-42	49	28	washout	washout	NOUN
eyereports-42	49	29	periods	period	NOUN
eyereports-42	49	30	when	when	SCONJ
eyereports-42	49	31	patients	patient	NOUN
eyereports-42	49	32	change	change	VERB
eyereports-42	49	33	medications	medication	NOUN
eyereports-42	49	34	or	or	CCONJ
eyereports-42	49	35	enter	enter	VERB
eyereports-42	49	36	controlled	control	VERB
eyereports-42	49	37	clinical	clinical	ADJ
eyereports-42	49	38	trials	trial	NOUN
eyereports-42	49	39	.	.	PUNCT
eyereports-42	50	1	a	a	DET
eyereports-42	50	2	reliable	reliable	ADJ
eyereports-42	50	3	mathematical	mathematical	ADJ
eyereports-42	50	4	model	model	NOUN
eyereports-42	50	5	would	would	AUX
eyereports-42	50	6	enable	enable	VERB
eyereports-42	50	7	physicians	physician	NOUN
eyereports-42	50	8	to	to	PART
eyereports-42	50	9	design	design	VERB
eyereports-42	50	10	better	well	ADJ
eyereports-42	50	11	clinical	clinical	ADJ
eyereports-42	50	12	studies	study	NOUN
eyereports-42	50	13	and	and	CCONJ
eyereports-42	50	14	provide	provide	VERB
eyereports-42	50	15	improved	improve	VERB
eyereports-42	50	16	patient	patient	ADJ
eyereports-42	50	17	care	care	NOUN
eyereports-42	50	18	.	.	PUNCT
eyereports-42	51	1	experimental	experimental	ADJ
eyereports-42	51	2	pharmacokinetic	pharmacokinetic	ADJ
eyereports-42	51	3	data	datum	NOUN
eyereports-42	51	4	from	from	ADP
eyereports-42	51	5	rabbits	rabbit	NOUN
eyereports-42	51	6	,	,	PUNCT
eyereports-42	51	7	monkeys	monkey	NOUN
eyereports-42	51	8	and	and	CCONJ
eyereports-42	51	9	humans	human	NOUN
eyereports-42	51	10	has	have	AUX
eyereports-42	51	11	been	be	AUX
eyereports-42	51	12	published	publish	VERB
eyereports-42	51	13	for	for	ADP
eyereports-42	51	14	the	the	DET
eyereports-42	51	15	3	3	NUM
eyereports-42	51	16	antibody	antibody	NOUN
eyereports-42	51	17	based	base	VERB
eyereports-42	51	18	anti	anti	ADJ
eyereports-42	51	19	-	-	ADJ
eyereports-42	51	20	vegf	vegf	ADJ
eyereports-42	51	21	drugs	drug	NOUN
eyereports-42	51	22	but	but	CCONJ
eyereports-42	51	23	only	only	ADV
eyereports-42	51	24	bevacizumab	bevacizumab	NOUN
eyereports-42	51	25	has	have	AUX
eyereports-42	51	26	been	be	AUX
eyereports-42	51	27	studied	study	VERB
eyereports-42	51	28	in	in	ADP
eyereports-42	51	29	all	all	DET
eyereports-42	51	30	3	3	NUM
eyereports-42	51	31	species.3,4,6	species.3,4,6	NOUN
eyereports-42	51	32	-	-	SYM
eyereports-42	51	33	13	13	NUM
eyereports-42	51	34	until	until	SCONJ
eyereports-42	51	35	human	human	ADJ
eyereports-42	51	36	data	datum	NOUN
eyereports-42	51	37	for	for	ADP
eyereports-42	51	38	ranibizumab	ranibizumab	NOUN
eyereports-42	51	39	and	and	CCONJ
eyereports-42	51	40	the	the	DET
eyereports-42	51	41	vte	vte	NOUN
eyereports-42	51	42	become	become	VERB
eyereports-42	51	43	available	available	ADJ
eyereports-42	51	44	,	,	PUNCT
eyereports-42	51	45	half	half	ADJ
eyereports-42	51	46	-	-	PUNCT
eyereports-42	51	47	life	life	NOUN
eyereports-42	51	48	calculations	calculation	NOUN
eyereports-42	51	49	based	base	VERB
eyereports-42	51	50	upon	upon	SCONJ
eyereports-42	51	51	a	a	DET
eyereports-42	51	52	methodically	methodically	ADV
eyereports-42	51	53	derived	derive	VERB
eyereports-42	51	54	mathematical	mathematical	ADJ
eyereports-42	51	55	model	model	NOUN
eyereports-42	51	56	may	may	AUX
eyereports-42	51	57	provide	provide	VERB
eyereports-42	51	58	the	the	DET
eyereports-42	51	59	most	most	ADV
eyereports-42	51	60	accurate	accurate	ADJ
eyereports-42	51	61	values	value	NOUN
eyereports-42	51	62	.	.	PUNCT
eyereports-42	52	1	published	publish	VERB
eyereports-42	52	2	reports	report	NOUN
eyereports-42	52	3	show	show	VERB
eyereports-42	52	4	that	that	SCONJ
eyereports-42	52	5	intravitreal	intravitreal	ADJ
eyereports-42	52	6	halflife	halflife	NOUN
eyereports-42	52	7	differences	difference	NOUN
eyereports-42	52	8	exist	exist	VERB
eyereports-42	52	9	even	even	ADV
eyereports-42	52	10	for	for	ADP
eyereports-42	52	11	the	the	DET
eyereports-42	52	12	same	same	ADJ
eyereports-42	52	13	drug	drug	NOUN
eyereports-42	52	14	within	within	ADP
eyereports-42	52	15	a	a	DET
eyereports-42	52	16	single	single	ADJ
eyereports-42	52	17	species	specie	NOUN
eyereports-42	52	18	.	.	PUNCT
eyereports-42	53	1	these	these	DET
eyereports-42	53	2	differences	difference	NOUN
eyereports-42	53	3	may	may	AUX
eyereports-42	53	4	be	be	AUX
eyereports-42	53	5	due	due	ADJ
eyereports-42	53	6	to	to	ADP
eyereports-42	53	7	several	several	ADJ
eyereports-42	53	8	factors	factor	NOUN
eyereports-42	53	9	including	include	VERB
eyereports-42	53	10	vitreous	vitreous	ADJ
eyereports-42	53	11	and	and	CCONJ
eyereports-42	53	12	aqueous	aqueous	ADJ
eyereports-42	53	13	sampling	sampling	NOUN
eyereports-42	53	14	techniques	technique	NOUN
eyereports-42	53	15	,	,	PUNCT
eyereports-42	53	16	drug	drug	NOUN
eyereports-42	53	17	reflux	reflux	NOUN
eyereports-42	53	18	at	at	ADP
eyereports-42	53	19	the	the	DET
eyereports-42	53	20	time	time	NOUN
eyereports-42	53	21	of	of	ADP
eyereports-42	53	22	injection	injection	NOUN
eyereports-42	53	23	,	,	PUNCT
eyereports-42	53	24	and	and	CCONJ
eyereports-42	53	25	drug	drug	NOUN
eyereports-42	53	26	assay	assay	NOUN
eyereports-42	53	27	technique	technique	NOUN
eyereports-42	53	28	and	and	CCONJ
eyereports-42	53	29	performance	performance	NOUN
eyereports-42	53	30	.	.	PUNCT
eyereports-42	54	1	when	when	SCONJ
eyereports-42	54	2	choosing	choose	VERB
eyereports-42	54	3	experimental	experimental	ADJ
eyereports-42	54	4	models	model	NOUN
eyereports-42	54	5	with	with	ADP
eyereports-42	54	6	which	which	PRON
eyereports-42	54	7	to	to	PART
eyereports-42	54	8	make	make	VERB
eyereports-42	54	9	half	half	ADJ
eyereports-42	54	10	-	-	PUNCT
eyereports-42	54	11	life	life	NOUN
eyereports-42	54	12	comparisons	comparison	NOUN
eyereports-42	54	13	between	between	ADP
eyereports-42	54	14	different	different	ADJ
eyereports-42	54	15	drugs	drug	NOUN
eyereports-42	54	16	,	,	PUNCT
eyereports-42	54	17	models	model	NOUN
eyereports-42	54	18	that	that	PRON
eyereports-42	54	19	test	test	VERB
eyereports-42	54	20	at	at	ADV
eyereports-42	54	21	least	least	ADV
eyereports-42	54	22	2	2	NUM
eyereports-42	54	23	drugs	drug	NOUN
eyereports-42	54	24	–	–	PUNCT
eyereports-42	54	25	bakri	bakri	NOUN
eyereports-42	54	26	et	et	PROPN
eyereports-42	54	27	al	al	PROPN
eyereports-42	54	28	.	.	PROPN
eyereports-42	54	29	’s	’s	PART
eyereports-42	54	30	rabbit	rabbit	NOUN
eyereports-42	54	31	model	model	NOUN
eyereports-42	54	32	and	and	CCONJ
eyereports-42	54	33	mordenti	mordenti	PROPN
eyereports-42	54	34	et	et	PROPN
eyereports-42	54	35	al	al	PROPN
eyereports-42	54	36	.	.	PROPN
eyereports-42	54	37	’s	’s	PART
eyereports-42	54	38	monkey	monkey	NOUN
eyereports-42	54	39	model	model	NOUN
eyereports-42	54	40	–	–	PUNCT
eyereports-42	54	41	would	would	AUX
eyereports-42	54	42	minimize	minimize	VERB
eyereports-42	54	43	artifactual	artifactual	ADJ
eyereports-42	54	44	differences	difference	NOUN
eyereports-42	54	45	.	.	PUNCT
eyereports-42	55	1	a	a	DET
eyereports-42	55	2	mathematical	mathematical	ADJ
eyereports-42	55	3	model	model	NOUN
eyereports-42	55	4	derived	derive	VERB
eyereports-42	55	5	from	from	ADP
eyereports-42	55	6	experimental	experimental	ADJ
eyereports-42	55	7	rabbit	rabbit	NOUN
eyereports-42	55	8	data5	data5	PROPN
eyereports-42	55	9	provides	provide	VERB
eyereports-42	55	10	the	the	DET
eyereports-42	55	11	best	good	ADJ
eyereports-42	55	12	starting	starting	NOUN
eyereports-42	55	13	point	point	NOUN
eyereports-42	55	14	for	for	ADP
eyereports-42	55	15	predicting	predict	VERB
eyereports-42	55	16	drug	drug	NOUN
eyereports-42	55	17	half	half	ADJ
eyereports-42	55	18	-	-	PUNCT
eyereports-42	55	19	lives	life	NOUN
eyereports-42	55	20	in	in	ADP
eyereports-42	55	21	other	other	ADJ
eyereports-42	55	22	species	specie	NOUN
eyereports-42	55	23	.	.	PUNCT
eyereports-42	56	1	this	this	DET
eyereports-42	56	2	model	model	NOUN
eyereports-42	56	3	was	be	AUX
eyereports-42	56	4	created	create	VERB
eyereports-42	56	5	from	from	ADP
eyereports-42	56	6	half	half	ADJ
eyereports-42	56	7	-	-	PUNCT
eyereports-42	56	8	life	life	NOUN
eyereports-42	56	9	data	datum	NOUN
eyereports-42	56	10	of	of	ADP
eyereports-42	56	11	over	over	ADP
eyereports-42	56	12	60	60	NUM
eyereports-42	56	13	drugs	drug	NOUN
eyereports-42	56	14	,	,	PUNCT
eyereports-42	56	15	including	include	VERB
eyereports-42	56	16	bevacizumab	bevacizumab	NOUN
eyereports-42	56	17	.	.	PUNCT
eyereports-42	57	1	according	accord	VERB
eyereports-42	57	2	to	to	ADP
eyereports-42	57	3	the	the	DET
eyereports-42	57	4	model	model	NOUN
eyereports-42	57	5	the	the	DET
eyereports-42	57	6	most	most	ADV
eyereports-42	57	7	important	important	ADJ
eyereports-42	57	8	determinant	determinant	ADJ
eyereports-42	57	9	of	of	ADP
eyereports-42	57	10	drug	drug	NOUN
eyereports-42	57	11	half	half	ADJ
eyereports-42	57	12	-	-	PUNCT
eyereports-42	57	13	life	life	NOUN
eyereports-42	57	14	is	be	AUX
eyereports-42	57	15	molecular	molecular	ADJ
eyereports-42	57	16	size	size	NOUN
eyereports-42	57	17	;	;	PUNCT
eyereports-42	57	18	less	less	ADV
eyereports-42	57	19	important	important	ADJ
eyereports-42	57	20	factors	factor	NOUN
eyereports-42	57	21	include	include	VERB
eyereports-42	57	22	lipophilicity	lipophilicity	NOUN
eyereports-42	57	23	,	,	PUNCT
eyereports-42	57	24	drug	drug	NOUN
eyereports-42	57	25	solubility	solubility	NOUN
eyereports-42	57	26	,	,	PUNCT
eyereports-42	57	27	dose	dose	NOUN
eyereports-42	57	28	,	,	PUNCT
eyereports-42	57	29	salt	salt	NOUN
eyereports-42	57	30	form	form	NOUN
eyereports-42	57	31	factor	factor	NOUN
eyereports-42	57	32	,	,	PUNCT
eyereports-42	57	33	and	and	CCONJ
eyereports-42	57	34	eye	eye	NOUN
eyereports-42	57	35	pigmentation	pigmentation	NOUN
eyereports-42	57	36	.	.	PUNCT
eyereports-42	58	1	the	the	DET
eyereports-42	58	2	model	model	NOUN
eyereports-42	58	3	predicts	predict	VERB
eyereports-42	58	4	that	that	SCONJ
eyereports-42	58	5	macromolecules	macromolecule	NOUN
eyereports-42	58	6	with	with	ADP
eyereports-42	58	7	similar	similar	ADJ
eyereports-42	58	8	structure	structure	NOUN
eyereports-42	58	9	(	(	PUNCT
eyereports-42	58	10	e.g.	e.g.	ADV
eyereports-42	58	11	fab	fab	ADJ
eyereports-42	58	12	antibody	antibody	NOUN
eyereports-42	58	13	fragments	fragment	NOUN
eyereports-42	58	14	or	or	CCONJ
eyereports-42	58	15	full	full	ADJ
eyereports-42	58	16	length	length	NOUN
eyereports-42	58	17	antibodies	antibodie	VERB
eyereports-42	58	18	)	)	PUNCT
eyereports-42	58	19	should	should	AUX
eyereports-42	58	20	have	have	VERB
eyereports-42	58	21	similar	similar	ADJ
eyereports-42	58	22	half	half	ADJ
eyereports-42	58	23	-	-	PUNCT
eyereports-42	58	24	lives	life	NOUN
eyereports-42	58	25	within	within	ADP
eyereports-42	58	26	a	a	DET
eyereports-42	58	27	given	give	VERB
eyereports-42	58	28	species	specie	NOUN
eyereports-42	58	29	.	.	PUNCT
eyereports-42	59	1	experimental	experimental	ADJ
eyereports-42	59	2	data	datum	NOUN
eyereports-42	59	3	with	with	ADP
eyereports-42	59	4	rituximab	rituximab	NOUN
eyereports-42	59	5	(	(	PUNCT
eyereports-42	59	6	mw	mw	PROPN
eyereports-42	59	7	145	145	NUM
eyereports-42	59	8	kd	kd	NOUN
eyereports-42	59	9	)	)	PUNCT
eyereports-42	59	10	–	–	PUNCT
eyereports-42	59	11	intravitreal	intravitreal	ADJ
eyereports-42	59	12	half	half	ADJ
eyereports-42	59	13	-	-	PUNCT
eyereports-42	59	14	life	life	NOUN
eyereports-42	59	15	of	of	ADP
eyereports-42	59	16	4.7	4.7	NUM
eyereports-42	59	17	days	day	NOUN
eyereports-42	59	18	in	in	ADP
eyereports-42	59	19	rabbits	rabbit	NOUN
eyereports-42	59	20	suggests	suggest	VERB
eyereports-42	59	21	this	this	PRON
eyereports-42	59	22	to	to	PART
eyereports-42	59	23	be	be	AUX
eyereports-42	59	24	true.14	true.14	PROPN
eyereports-42	59	25	since	since	SCONJ
eyereports-42	59	26	lipophilicity	lipophilicity	NOUN
eyereports-42	59	27	,	,	PUNCT
eyereports-42	59	28	drug	drug	NOUN
eyereports-42	59	29	solubility	solubility	NOUN
eyereports-42	59	30	,	,	PUNCT
eyereports-42	59	31	and	and	CCONJ
eyereports-42	59	32	salt	salt	NOUN
eyereports-42	59	33	form	form	NOUN
eyereports-42	59	34	factor	factor	NOUN
eyereports-42	59	35	are	be	AUX
eyereports-42	59	36	independent	independent	ADJ
eyereports-42	59	37	of	of	ADP
eyereports-42	59	38	the	the	DET
eyereports-42	59	39	vitreous	vitreous	ADJ
eyereports-42	59	40	volume	volume	NOUN
eyereports-42	59	41	,	,	PUNCT
eyereports-42	59	42	the	the	DET
eyereports-42	59	43	model	model	NOUN
eyereports-42	59	44	was	be	AUX
eyereports-42	59	45	altered	alter	VERB
eyereports-42	59	46	by	by	ADP
eyereports-42	59	47	changing	change	VERB
eyereports-42	59	48	only	only	ADV
eyereports-42	59	49	the	the	DET
eyereports-42	59	50	slope	slope	NOUN
eyereports-42	59	51	coefficient	coefficient	NOUN
eyereports-42	59	52	.	.	PUNCT
eyereports-42	60	1	bevacizumab	bevacizumab	PROPN
eyereports-42	60	2	data	data	PROPN
eyereports-42	60	3	exists	exist	VERB
eyereports-42	60	4	for	for	ADP
eyereports-42	60	5	all	all	DET
eyereports-42	60	6	3	3	NUM
eyereports-42	60	7	species	specie	NOUN
eyereports-42	60	8	so	so	SCONJ
eyereports-42	60	9	its	its	PRON
eyereports-42	60	10	half	half	ADJ
eyereports-42	60	11	-	-	PUNCT
eyereports-42	60	12	lives	life	NOUN
eyereports-42	60	13	were	be	AUX
eyereports-42	60	14	used	use	VERB
eyereports-42	60	15	to	to	PART
eyereports-42	60	16	guide	guide	VERB
eyereports-42	60	17	changes	change	NOUN
eyereports-42	60	18	of	of	ADP
eyereports-42	60	19	the	the	DET
eyereports-42	60	20	slope	slope	NOUN
eyereports-42	60	21	coefficient	coefficient	NOUN
eyereports-42	60	22	within	within	ADP
eyereports-42	60	23	the	the	DET
eyereports-42	60	24	mathematical	mathematical	ADJ
eyereports-42	60	25	model	model	NOUN
eyereports-42	60	26	.	.	PUNCT
eyereports-42	61	1	these	these	DET
eyereports-42	61	2	changes	change	NOUN
eyereports-42	61	3	were	be	AUX
eyereports-42	61	4	made	make	VERB
eyereports-42	61	5	with	with	ADP
eyereports-42	61	6	3	3	NUM
eyereports-42	61	7	goals	goal	NOUN
eyereports-42	61	8	in	in	ADP
eyereports-42	61	9	mind	mind	NOUN
eyereports-42	61	10	:	:	PUNCT
eyereports-42	61	11	i	i	NOUN
eyereports-42	61	12	)	)	PUNCT
eyereports-42	61	13	to	to	PART
eyereports-42	61	14	establish	establish	VERB
eyereports-42	61	15	validity	validity	NOUN
eyereports-42	61	16	of	of	ADP
eyereports-42	61	17	the	the	DET
eyereports-42	61	18	model	model	NOUN
eyereports-42	61	19	in	in	ADP
eyereports-42	61	20	rabbits	rabbit	NOUN
eyereports-42	61	21	;	;	PUNCT
eyereports-42	61	22	ii	ii	X
eyereports-42	61	23	)	)	PUNCT
eyereports-42	61	24	to	to	PART
eyereports-42	61	25	establish	establish	VERB
eyereports-42	61	26	mutability	mutability	NOUN
eyereports-42	61	27	of	of	ADP
eyereports-42	61	28	the	the	DET
eyereports-42	61	29	model	model	NOUN
eyereports-42	61	30	to	to	ADP
eyereports-42	61	31	monkeys	monkey	NOUN
eyereports-42	61	32	;	;	PUNCT
eyereports-42	61	33	iii	iii	X
eyereports-42	61	34	)	)	PUNCT
eyereports-42	61	35	to	to	PART
eyereports-42	61	36	calculate	calculate	VERB
eyereports-42	61	37	half	half	ADJ
eyereports-42	61	38	-	-	PUNCT
eyereports-42	61	39	lives	life	NOUN
eyereports-42	61	40	of	of	ADP
eyereports-42	61	41	ranibizumab	ranibizumab	NOUN
eyereports-42	61	42	and	and	CCONJ
eyereports-42	61	43	vte	vte	NOUN
eyereports-42	61	44	in	in	ADP
eyereports-42	61	45	humans	human	NOUN
eyereports-42	61	46	.	.	PUNCT
eyereports-42	62	1	the	the	DET
eyereports-42	62	2	bevacizumab	bevacizumab	NOUN
eyereports-42	62	3	guided	guide	VERB
eyereports-42	62	4	changes	change	NOUN
eyereports-42	62	5	in	in	ADP
eyereports-42	62	6	the	the	DET
eyereports-42	62	7	model	model	NOUN
eyereports-42	62	8	produced	produce	VERB
eyereports-42	62	9	ranibizumab	ranibizumab	NOUN
eyereports-42	62	10	values	value	NOUN
eyereports-42	62	11	of	of	ADP
eyereports-42	62	12	2.64	2.64	NUM
eyereports-42	62	13	days	day	NOUN
eyereports-42	62	14	in	in	ADP
eyereports-42	62	15	the	the	DET
eyereports-42	62	16	rabbit	rabbit	NOUN
eyereports-42	62	17	and	and	CCONJ
eyereports-42	62	18	3.34	3.34	NUM
eyereports-42	62	19	days	day	NOUN
eyereports-42	62	20	the	the	DET
eyereports-42	62	21	monkey	monkey	NOUN
eyereports-42	62	22	,	,	PUNCT
eyereports-42	62	23	differing	differ	VERB
eyereports-42	62	24	from	from	ADP
eyereports-42	62	25	the	the	DET
eyereports-42	62	26	experimental	experimental	ADJ
eyereports-42	62	27	values	value	NOUN
eyereports-42	62	28	by	by	ADP
eyereports-42	62	29	only	only	ADV
eyereports-42	62	30	8.3	8.3	NUM
eyereports-42	62	31	%	%	NOUN
eyereports-42	62	32	and	and	CCONJ
eyereports-42	62	33	4.2	4.2	NUM
eyereports-42	62	34	%	%	NOUN
eyereports-42	62	35	.	.	PUNCT
eyereports-42	63	1	this	this	DET
eyereports-42	63	2	finding	finding	NOUN
eyereports-42	63	3	suggested	suggest	VERB
eyereports-42	63	4	that	that	SCONJ
eyereports-42	63	5	the	the	DET
eyereports-42	63	6	model	model	NOUN
eyereports-42	63	7	was	be	AUX
eyereports-42	63	8	accurate	accurate	ADJ
eyereports-42	63	9	for	for	ADP
eyereports-42	63	10	macromolecule	macromolecule	NOUN
eyereports-42	63	11	halflives	halflive	NOUN
eyereports-42	63	12	in	in	ADP
eyereports-42	63	13	rabbit	rabbit	NOUN
eyereports-42	63	14	eyes	eye	NOUN
eyereports-42	63	15	and	and	CCONJ
eyereports-42	63	16	mutable	mutable	ADJ
eyereports-42	63	17	to	to	ADP
eyereports-42	63	18	monkey	monkey	NOUN
eyereports-42	63	19	eyes	eye	NOUN
eyereports-42	63	20	.	.	PUNCT
eyereports-42	64	1	given	give	VERB
eyereports-42	64	2	these	these	DET
eyereports-42	64	3	findings	finding	NOUN
eyereports-42	64	4	,	,	PUNCT
eyereports-42	64	5	the	the	DET
eyereports-42	64	6	model	model	NOUN
eyereports-42	64	7	was	be	AUX
eyereports-42	64	8	used	use	VERB
eyereports-42	64	9	to	to	PART
eyereports-42	64	10	calculate	calculate	VERB
eyereports-42	64	11	the	the	DET
eyereports-42	64	12	half	half	ADJ
eyereports-42	64	13	-	-	PUNCT
eyereports-42	64	14	lives	life	NOUN
eyereports-42	64	15	of	of	ADP
eyereports-42	64	16	ranibizumab	ranibizumab	NOUN
eyereports-42	64	17	(	(	PUNCT
eyereports-42	64	18	4.75	4.75	NUM
eyereports-42	64	19	days	day	NOUN
eyereports-42	64	20	)	)	PUNCT
eyereports-42	64	21	and	and	CCONJ
eyereports-42	64	22	the	the	DET
eyereports-42	64	23	vte	vte	NOUN
eyereports-42	64	24	(	(	PUNCT
eyereports-42	64	25	7.13	7.13	NUM
eyereports-42	64	26	days	day	NOUN
eyereports-42	64	27	)	)	PUNCT
eyereports-42	64	28	in	in	ADP
eyereports-42	64	29	humans	human	NOUN
eyereports-42	64	30	.	.	PUNCT
eyereports-42	65	1	both	both	PRON
eyereports-42	65	2	published	publish	VERB
eyereports-42	65	3	experimental	experimental	ADJ
eyereports-42	65	4	results	result	NOUN
eyereports-42	65	5	and	and	CCONJ
eyereports-42	65	6	the	the	DET
eyereports-42	65	7	halflife	halflife	NOUN
eyereports-42	65	8	calculations	calculation	NOUN
eyereports-42	65	9	obtained	obtain	VERB
eyereports-42	65	10	with	with	ADP
eyereports-42	65	11	this	this	DET
eyereports-42	65	12	adapted	adapt	VERB
eyereports-42	65	13	model	model	NOUN
eyereports-42	65	14	are	be	AUX
eyereports-42	65	15	consistent	consistent	ADJ
eyereports-42	65	16	with	with	ADP
eyereports-42	65	17	2	2	NUM
eyereports-42	65	18	commonly	commonly	ADV
eyereports-42	65	19	held	hold	VERB
eyereports-42	65	20	principles	principle	NOUN
eyereports-42	65	21	of	of	ADP
eyereports-42	65	22	intraocular	intraocular	ADJ
eyereports-42	65	23	drug	drug	NOUN
eyereports-42	65	24	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	65	25	.	.	PUNCT
eyereports-42	66	1	firstly	firstly	ADV
eyereports-42	66	2	,	,	PUNCT
eyereports-42	66	3	the	the	DET
eyereports-42	66	4	intravitreal	intravitreal	ADJ
eyereports-42	66	5	half	half	ADJ
eyereports-42	66	6	-	-	PUNCT
eyereports-42	66	7	life	life	NOUN
eyereports-42	66	8	of	of	ADP
eyereports-42	66	9	a	a	DET
eyereports-42	66	10	given	give	VERB
eyereports-42	66	11	drug	drug	NOUN
eyereports-42	66	12	increases	increase	NOUN
eyereports-42	66	13	with	with	ADP
eyereports-42	66	14	the	the	DET
eyereports-42	66	15	size	size	NOUN
eyereports-42	66	16	of	of	ADP
eyereports-42	66	17	the	the	DET
eyereports-42	66	18	eye	eye	NOUN
eyereports-42	66	19	.	.	PUNCT
eyereports-42	67	1	when	when	SCONJ
eyereports-42	67	2	the	the	DET
eyereports-42	67	3	slope	slope	NOUN
eyereports-42	67	4	coefficient	coefficient	NOUN
eyereports-42	67	5	is	be	AUX
eyereports-42	67	6	graphed	graph	VERB
eyereports-42	67	7	against	against	ADP
eyereports-42	67	8	the	the	DET
eyereports-42	67	9	size	size	NOUN
eyereports-42	67	10	of	of	ADP
eyereports-42	67	11	the	the	DET
eyereports-42	67	12	eye	eye	NOUN
eyereports-42	67	13	a	a	DET
eyereports-42	67	14	highly	highly	ADV
eyereports-42	67	15	correlated	correlate	VERB
eyereports-42	67	16	(	(	PUNCT
eyereports-42	67	17	r2=0.9956	r2=0.9956	NOUN
eyereports-42	67	18	)	)	PUNCT
eyereports-42	67	19	linear	linear	PROPN
eyereports-42	67	20	relationship	relationship	NOUN
eyereports-42	67	21	is	be	AUX
eyereports-42	67	22	seen	see	VERB
eyereports-42	67	23	.	.	PUNCT
eyereports-42	68	1	this	this	DET
eyereports-42	68	2	limited	limited	ADJ
eyereports-42	68	3	experimental	experimental	ADJ
eyereports-42	68	4	data	datum	NOUN
eyereports-42	68	5	suggests	suggest	VERB
eyereports-42	68	6	that	that	SCONJ
eyereports-42	68	7	the	the	DET
eyereports-42	68	8	half	half	ADJ
eyereports-42	68	9	-	-	PUNCT
eyereports-42	68	10	life	life	NOUN
eyereports-42	68	11	of	of	ADP
eyereports-42	68	12	a	a	DET
eyereports-42	68	13	drug	drug	NOUN
eyereports-42	68	14	in	in	ADP
eyereports-42	68	15	one	one	NUM
eyereports-42	68	16	species	specie	NOUN
eyereports-42	68	17	may	may	AUX
eyereports-42	68	18	be	be	AUX
eyereports-42	68	19	predicted	predict	VERB
eyereports-42	68	20	based	base	VERB
eyereports-42	68	21	upon	upon	SCONJ
eyereports-42	68	22	experimental	experimental	ADJ
eyereports-42	68	23	data	datum	NOUN
eyereports-42	68	24	in	in	ADP
eyereports-42	68	25	other	other	ADJ
eyereports-42	68	26	species	specie	NOUN
eyereports-42	68	27	.	.	PUNCT
eyereports-42	69	1	more	more	ADJ
eyereports-42	69	2	work	work	NOUN
eyereports-42	69	3	,	,	PUNCT
eyereports-42	69	4	however	however	ADV
eyereports-42	69	5	,	,	PUNCT
eyereports-42	69	6	needs	need	VERB
eyereports-42	69	7	to	to	PART
eyereports-42	69	8	be	be	AUX
eyereports-42	69	9	done	do	VERB
eyereports-42	69	10	to	to	PART
eyereports-42	69	11	determine	determine	VERB
eyereports-42	69	12	the	the	DET
eyereports-42	69	13	validity	validity	NOUN
eyereports-42	69	14	of	of	ADP
eyereports-42	69	15	such	such	DET
eyereports-42	69	16	a	a	DET
eyereports-42	69	17	mathematical	mathematical	ADJ
eyereports-42	69	18	relationship	relationship	NOUN
eyereports-42	69	19	.	.	PUNCT
eyereports-42	70	1	secondly	secondly	ADV
eyereports-42	70	2	,	,	PUNCT
eyereports-42	70	3	the	the	DET
eyereports-42	70	4	half	half	ADJ
eyereports-42	70	5	-	-	PUNCT
eyereports-42	70	6	lives	life	NOUN
eyereports-42	70	7	of	of	ADP
eyereports-42	70	8	drugs	drug	NOUN
eyereports-42	70	9	with	with	ADP
eyereports-42	70	10	similar	similar	ADJ
eyereports-42	70	11	structures	structure	NOUN
eyereports-42	70	12	increase	increase	VERB
eyereports-42	70	13	according	accord	VERB
eyereports-42	70	14	to	to	ADP
eyereports-42	70	15	the	the	DET
eyereports-42	70	16	logarithm	logarithm	NOUN
eyereports-42	70	17	of	of	ADP
eyereports-42	70	18	molecular	molecular	ADJ
eyereports-42	70	19	weight	weight	NOUN
eyereports-42	70	20	.	.	PUNCT
eyereports-42	71	1	this	this	PRON
eyereports-42	71	2	suggests	suggest	VERB
eyereports-42	71	3	that	that	SCONJ
eyereports-42	71	4	for	for	ADP
eyereports-42	71	5	the	the	DET
eyereports-42	71	6	anti	anti	ADJ
eyereports-42	71	7	-	-	ADJ
eyereports-42	71	8	vegf	vegf	ADJ
eyereports-42	71	9	drugs	drug	NOUN
eyereports-42	71	10	the	the	DET
eyereports-42	71	11	intravitreal	intravitreal	ADJ
eyereports-42	71	12	halflives	halflive	NOUN
eyereports-42	71	13	should	should	AUX
eyereports-42	71	14	rank	rank	VERB
eyereports-42	71	15	as	as	SCONJ
eyereports-42	71	16	follows	follow	VERB
eyereports-42	71	17	:	:	PUNCT
eyereports-42	71	18	bevacizumab	bevacizumab	NOUN
eyereports-42	71	19	>	>	X
eyereports-42	71	20	vte	vte	PROPN
eyereports-42	71	21	>	>	X
eyereports-42	71	22	ranibizumab	ranibizumab	NOUN
eyereports-42	71	23	.	.	PUNCT
eyereports-42	72	1	the	the	DET
eyereports-42	72	2	major	major	ADJ
eyereports-42	72	3	weakness	weakness	NOUN
eyereports-42	72	4	of	of	ADP
eyereports-42	72	5	this	this	DET
eyereports-42	72	6	model	model	NOUN
eyereports-42	72	7	concerns	concern	VERB
eyereports-42	72	8	the	the	DET
eyereports-42	72	9	mutability	mutability	NOUN
eyereports-42	72	10	of	of	ADP
eyereports-42	72	11	the	the	DET
eyereports-42	72	12	rabbit	rabbit	NOUN
eyereports-42	72	13	-	-	PUNCT
eyereports-42	72	14	determined	determine	VERB
eyereports-42	72	15	model	model	NOUN
eyereports-42	72	16	between	between	ADP
eyereports-42	72	17	species	specie	NOUN
eyereports-42	72	18	.	.	PUNCT
eyereports-42	73	1	though	though	SCONJ
eyereports-42	73	2	changing	change	VERB
eyereports-42	73	3	the	the	DET
eyereports-42	73	4	slope	slope	NOUN
eyereports-42	73	5	coefficient	coefficient	NOUN
eyereports-42	73	6	seems	seem	VERB
eyereports-42	73	7	a	a	DET
eyereports-42	73	8	logical	logical	ADJ
eyereports-42	73	9	transformation	transformation	NOUN
eyereports-42	73	10	,	,	PUNCT
eyereports-42	73	11	the	the	DET
eyereports-42	73	12	validity	validity	NOUN
eyereports-42	73	13	of	of	ADP
eyereports-42	73	14	this	this	DET
eyereports-42	73	15	strategy	strategy	NOUN
eyereports-42	73	16	must	must	AUX
eyereports-42	73	17	await	await	VERB
eyereports-42	73	18	confirmation	confirmation	NOUN
eyereports-42	73	19	with	with	ADP
eyereports-42	73	20	experimental	experimental	ADJ
eyereports-42	73	21	data	datum	NOUN
eyereports-42	73	22	.	.	PUNCT
eyereports-42	74	1	references	reference	NOUN
eyereports-42	74	2	1	1	NUM
eyereports-42	74	3	.	.	PUNCT
eyereports-42	74	4	stewart	stewart	PROPN
eyereports-42	74	5	mw	mw	PROPN
eyereports-42	74	6	.	.	PROPN
eyereports-42	74	7	predicted	predict	VERB
eyereports-42	74	8	biologic	biologic	NOUN
eyereports-42	74	9	activity	activity	NOUN
eyereports-42	74	10	of	of	ADP
eyereports-42	74	11	intravitreal	intravitreal	ADJ
eyereports-42	74	12	bevacizumab	bevacizumab	NOUN
eyereports-42	74	13	.	.	PUNCT
eyereports-42	74	14	retina	retina	VERB
eyereports-42	74	15	2007;27	2007;27	NOUN
eyereports-42	74	16	:	:	PUNCT
eyereports-42	74	17	1196	1196	NUM
eyereports-42	74	18	-	-	SYM
eyereports-42	74	19	200	200	NUM
eyereports-42	74	20	.	.	NOUN
eyereports-42	75	1	2	2	X
eyereports-42	75	2	.	.	X
eyereports-42	75	3	stewart	stewart	PROPN
eyereports-42	75	4	mw	mw	PROPN
eyereports-42	75	5	,	,	PUNCT
eyereports-42	75	6	rosenfeld	rosenfeld	PROPN
eyereports-42	75	7	p.	p.	PROPN
eyereports-42	75	8	predicted	predict	VERB
eyereports-42	75	9	biological	biological	ADJ
eyereports-42	75	10	activity	activity	NOUN
eyereports-42	75	11	of	of	ADP
eyereports-42	75	12	intravitreal	intravitreal	ADJ
eyereports-42	75	13	vegf	vegf	PROPN
eyereports-42	75	14	trap	trap	NOUN
eyereports-42	75	15	.	.	PUNCT
eyereports-42	76	1	br	br	PROPN
eyereports-42	77	1	j	j	PROPN
eyereports-42	77	2	ophthalmol	ophthalmol	PROPN
eyereports-42	77	3	2008;92:667	2008;92:667	NUM
eyereports-42	77	4	-	-	SYM
eyereports-42	77	5	8	8	NUM
eyereports-42	77	6	.	.	NOUN
eyereports-42	77	7	3	3	X
eyereports-42	77	8	.	.	X
eyereports-42	77	9	gaudreault	gaudreault	PROPN
eyereports-42	77	10	j	j	PROPN
eyereports-42	77	11	,	,	PUNCT
eyereports-42	77	12	webb	webb	PROPN
eyereports-42	77	13	w	w	PROPN
eyereports-42	77	14	,	,	PUNCT
eyereports-42	77	15	van	van	PROPN
eyereports-42	77	16	hoy	hoy	PROPN
eyereports-42	77	17	m	m	PROPN
eyereports-42	77	18	,	,	PUNCT
eyereports-42	77	19	et	et	PROPN
eyereports-42	77	20	al	al	PROPN
eyereports-42	77	21	.	.	PUNCT
eyereports-42	77	22	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	77	23	and	and	CCONJ
eyereports-42	77	24	retinal	retinal	ADJ
eyereports-42	77	25	distribution	distribution	NOUN
eyereports-42	77	26	of	of	ADP
eyereports-42	77	27	amd	amd	PROPN
eyereports-42	77	28	rhufab	rhufab	NOUN
eyereports-42	77	29	v2	v2	PROPN
eyereports-42	77	30	after	after	ADP
eyereports-42	77	31	intravitreal	intravitreal	ADJ
eyereports-42	77	32	administration	administration	NOUN
eyereports-42	77	33	in	in	ADP
eyereports-42	77	34	rabbits	rabbit	NOUN
eyereports-42	77	35	.	.	PUNCT
eyereports-42	78	1	aaps	aap	NOUN
eyereports-42	78	2	pharm	pharm	PROPN
eyereports-42	78	3	sci	sci	PROPN
eyereports-42	78	4	1999;suppl	1999;suppl	PROPN
eyereports-42	78	5	1:2142	1:2142	NUM
eyereports-42	78	6	.	.	PUNCT
eyereports-42	79	1	article	article	NOUN
eyereports-42	79	2	figure	figure	VERB
eyereports-42	79	3	1	1	NUM
eyereports-42	79	4	.	.	PUNCT
eyereports-42	79	5	intravitreal	intravitreal	ADJ
eyereports-42	79	6	volume	volume	NOUN
eyereports-42	79	7	is	be	AUX
eyereports-42	79	8	graphed	graph	VERB
eyereports-42	79	9	against	against	ADP
eyereports-42	79	10	the	the	DET
eyereports-42	79	11	slope	slope	NOUN
eyereports-42	79	12	coefficient	coefficient	NOUN
eyereports-42	79	13	of	of	ADP
eyereports-42	79	14	the	the	DET
eyereports-42	79	15	mathematical	mathematical	ADJ
eyereports-42	79	16	model	model	NOUN
eyereports-42	79	17	,	,	PUNCT
eyereports-42	79	18	as	as	SCONJ
eyereports-42	79	19	determined	determine	VERB
eyereports-42	79	20	by	by	ADP
eyereports-42	79	21	bevacizumab	bevacizumab	NOUN
eyereports-42	79	22	half	half	ADJ
eyereports-42	79	23	-	-	PUNCT
eyereports-42	79	24	lives	life	NOUN
eyereports-42	79	25	.	.	PUNCT
eyereports-42	80	1	table	table	NOUN
eyereports-42	80	2	1	1	NUM
eyereports-42	80	3	.	.	PUNCT
eyereports-42	81	1	intraocular	intraocular	ADJ
eyereports-42	81	2	half	half	ADJ
eyereports-42	81	3	-	-	PUNCT
eyereports-42	81	4	lives	life	NOUN
eyereports-42	81	5	of	of	ADP
eyereports-42	81	6	ranibizumab	ranibizumab	NOUN
eyereports-42	81	7	,	,	PUNCT
eyereports-42	81	8	vte	vte	NOUN
eyereports-42	81	9	,	,	PUNCT
eyereports-42	81	10	bevacizumab	bevacizumab	NOUN
eyereports-42	81	11	and	and	CCONJ
eyereports-42	81	12	similar	similar	ADJ
eyereports-42	81	13	macromolecules	macromolecule	NOUN
eyereports-42	81	14	are	be	AUX
eyereports-42	81	15	listed	list	VERB
eyereports-42	81	16	.	.	PUNCT
eyereports-42	82	1	authors	author	NOUN
eyereports-42	82	2	drug	drug	VERB
eyereports-42	82	3	species	specie	NOUN
eyereports-42	82	4	half	half	ADJ
eyereports-42	82	5	-	-	PUNCT
eyereports-42	82	6	life	life	NOUN
eyereports-42	82	7	bakri8	bakri8	NOUN
eyereports-42	82	8	ranibizumab	ranibizumab	NOUN
eyereports-42	82	9	rabbit	rabbit	NOUN
eyereports-42	82	10	2.88	2.88	NUM
eyereports-42	82	11	days	day	NOUN
eyereports-42	82	12	gaudreault11	gaudreault11	NOUN
eyereports-42	82	13	ranibizumab	ranibizumab	NOUN
eyereports-42	82	14	rabbit	rabbit	NOUN
eyereports-42	82	15	2.89	2.89	NUM
eyereports-42	82	16	days	day	NOUN
eyereports-42	82	17	regeneron	regeneron	NOUN
eyereports-42	82	18	vte	vte	NOUN
eyereports-42	82	19	rabbit	rabbit	NOUN
eyereports-42	82	20	4.79	4.79	NUM
eyereports-42	82	21	days	day	NOUN
eyereports-42	82	22	bakri7	bakri7	NOUN
eyereports-42	83	1	bevacizumab	bevacizumab	PROPN
eyereports-42	83	2	rabbit	rabbit	NOUN
eyereports-42	83	3	4.32	4.32	NUM
eyereports-42	83	4	days	day	NOUN
eyereports-42	83	5	nomoto12	nomoto12	PROPN
eyereports-42	83	6	bevacizumab	bevacizumab	PROPN
eyereports-42	83	7	rabbit	rabbit	NOUN
eyereports-42	83	8	5.95	5.95	NUM
eyereports-42	83	9	days	day	NOUN
eyereports-42	83	10	miyake13	miyake13	PROPN
eyereports-42	83	11	bevacizumab	bevacizumab	PROPN
eyereports-42	83	12	rabbit	rabbit	NOUN
eyereports-42	83	13	2.8	2.8	NUM
eyereports-42	83	14	days	day	NOUN
eyereports-42	83	15	(	(	PUNCT
eyereports-42	83	16	aqueous	aqueous	ADJ
eyereports-42	83	17	)	)	PUNCT
eyereports-42	83	18	kim14	kim14	PROPN
eyereports-42	83	19	infliximab	infliximab	NOUN
eyereports-42	83	20	rabbit	rabbit	NOUN
eyereports-42	83	21	4.7	4.7	NUM
eyereports-42	83	22	days	day	NOUN
eyereports-42	83	23	gaudreault4	gaudreault4	PROPN
eyereports-42	83	24	ranibizumab	ranibizumab	PROPN
eyereports-42	83	25	monkey	monkey	PROPN
eyereports-42	83	26	2.63	2.63	NUM
eyereports-42	83	27	days	day	NOUN
eyereports-42	83	28	(	(	PUNCT
eyereports-42	83	29	0.5	0.5	NUM
eyereports-42	83	30	mg)0	mg)0	PROPN
eyereports-42	83	31	gaudreault4	gaudreault4	PROPN
eyereports-42	83	32	ranibizumab	ranibizumab	PROPN
eyereports-42	83	33	monkey	monkey	PROPN
eyereports-42	83	34	3.9	3.9	NUM
eyereports-42	83	35	days	day	NOUN
eyereports-42	83	36	(	(	PUNCT
eyereports-42	83	37	2.0	2.0	NUM
eyereports-42	83	38	mg	mg	NOUN
eyereports-42	83	39	)	)	PUNCT
eyereports-42	83	40	mordenti6	mordenti6	PROPN
eyereports-42	84	1	fab	fab	PROPN
eyereports-42	84	2	monkey	monkey	PROPN
eyereports-42	84	3	3.2	3.2	NUM
eyereports-42	84	4	days	day	NOUN
eyereports-42	84	5	mordenti6	mordenti6	PROPN
eyereports-42	85	1	her2	her2	PROPN
eyereports-42	85	2	monkey	monkey	NOUN
eyereports-42	85	3	5.6	5.6	NUM
eyereports-42	85	4	days	day	NOUN
eyereports-42	85	5	zhu10	zhu10	PROPN
eyereports-42	85	6	bevacizumab	bevacizumab	PROPN
eyereports-42	85	7	human	human	ADJ
eyereports-42	85	8	6.7	6.7	NUM
eyereports-42	85	9	days	day	NOUN
eyereports-42	85	10	krohne9	krohne9	PROPN
eyereports-42	85	11	bevacizumab	bevacizumab	ADJ
eyereports-42	85	12	human	human	ADJ
eyereports-42	85	13	9.82	9.82	NUM
eyereports-42	85	14	days	day	NOUN
eyereports-42	85	15	(	(	PUNCT
eyereports-42	85	16	aqueous	aqueous	ADJ
eyereports-42	85	17	)	)	PUNCT
eyereports-42	85	18	intravitreal	intravitreal	NOUN
eyereports-42	85	19	volume	volume	NOUN
eyereports-42	85	20	(	(	PUNCT
eyereports-42	85	21	ml	ml	NOUN
eyereports-42	85	22	)	)	PUNCT
eyereports-42	85	23	s	s	PART
eyereports-42	86	1	lo	lo	NOUN
eyereports-42	86	2	p	p	NOUN
eyereports-42	86	3	e	e	X
eyereports-42	86	4	c	c	NOUN
eyereports-42	86	5	o	o	X
eyereports-42	86	6	e	e	X
eyereports-42	86	7	ff	ff	INTJ
eyereports-42	86	8	ic	ic	PROPN
eyereports-42	86	9	ie	ie	PROPN
eyereports-42	86	10	n	n	PROPN
eyereports-42	86	11	t	t	PROPN
eyereports-42	86	12	0.5	0.5	NUM
eyereports-42	86	13	0.49	0.49	NUM
eyereports-42	86	14	0.48	0.48	NUM
eyereports-42	86	15	0.47	0.47	NUM
eyereports-42	86	16	0.46	0.46	NUM
eyereports-42	86	17	0.45	0.45	NUM
eyereports-42	86	18	0.44	0.44	NUM
eyereports-42	86	19	0.43	0.43	NUM
eyereports-42	86	20	0	0	NUM
eyereports-42	86	21	0.5	0.5	NUM
eyereports-42	86	22	1	1	NUM
eyereports-42	86	23	1.5	1.5	NUM
eyereports-42	86	24	2	2	NUM
eyereports-42	86	25	2.5	2.5	NUM
eyereports-42	86	26	3	3	NUM
eyereports-42	86	27	.3.5	.3.5	SYM
eyereports-42	86	28	4	4	NUM
eyereports-42	86	29	4.5	4.5	NUM
eyereports-42	86	30	5	5	NUM
eyereports-42	86	31	y=	y=	NUM
eyereports-42	86	32	0.0178x+0.4107	0.0178x+0.4107	PROPN
eyereports-42	86	33	r2=0.9956	r2=0.9956	PROPN
eyereports-42	86	34	non	non	PROPN
eyereports-42	86	35	-co	-co	PROPN
eyereports-42	86	36	mmerc	mmerc	PROPN
eyereports-42	86	37	ial	ial	PROPN
eyereports-42	86	38	us	us	PROPN
eyereports-42	86	39	e	e	NOUN
eyereports-42	86	40	o	o	NOUN
eyereports-42	87	1	nly	nly	ADV
eyereports-42	87	2	[	[	X
eyereports-42	87	3	page	page	NOUN
eyereports-42	87	4	14	14	NUM
eyereports-42	87	5	]	]	PUNCT
eyereports-42	88	1	[	[	X
eyereports-42	88	2	eye	eye	NOUN
eyereports-42	88	3	reports	report	VERB
eyereports-42	88	4	2011	2011	NUM
eyereports-42	88	5	;	;	PUNCT
eyereports-42	88	6	1	1	NUM
eyereports-42	88	7	:	:	PUNCT
eyereports-42	88	8	e5	e5	X
eyereports-42	88	9	]	]	X
eyereports-42	88	10	4	4	X
eyereports-42	88	11	.	.	PUNCT
eyereports-42	88	12	gaudreault	gaudreault	PROPN
eyereports-42	88	13	j	j	PROPN
eyereports-42	88	14	,	,	PUNCT
eyereports-42	88	15	fei	fei	PROPN
eyereports-42	88	16	d	d	PROPN
eyereports-42	88	17	,	,	PUNCT
eyereports-42	88	18	rusit	rusit	PROPN
eyereports-42	88	19	j	j	PROPN
eyereports-42	88	20	,	,	PUNCT
eyereports-42	88	21	et	et	PROPN
eyereports-42	88	22	al	al	PROPN
eyereports-42	88	23	.	.	PROPN
eyereports-42	88	24	preclinical	preclinical	ADJ
eyereports-42	88	25	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	88	26	of	of	ADP
eyereports-42	88	27	ranibizu	ranibizu	PROPN
eyereports-42	88	28	mab	mab	NOUN
eyereports-42	88	29	(	(	PUNCT
eyereports-42	88	30	rhufabv2	rhufabv2	PROPN
eyereports-42	88	31	)	)	PUNCT
eyereports-42	88	32	after	after	ADP
eyereports-42	88	33	a	a	DET
eyereports-42	88	34	single	single	ADJ
eyereports-42	88	35	intravitreal	intravitreal	NOUN
eyereports-42	88	36	administration	administration	NOUN
eyereports-42	88	37	.	.	PUNCT
eyereports-42	89	1	invest	invest	VERB
eyereports-42	89	2	ophthalmol	ophthalmol	PROPN
eyereports-42	89	3	vis	vis	X
eyereports-42	89	4	sci	sci	PROPN
eyereports-42	89	5	2005;46:726	2005;46:726	PROPN
eyereports-42	89	6	-	-	SYM
eyereports-42	89	7	33	33	NUM
eyereports-42	89	8	.	.	NOUN
eyereports-42	90	1	5	5	NUM
eyereports-42	90	2	.	.	NUM
eyereports-42	90	3	durairaj	durairaj	VERB
eyereports-42	90	4	c	c	PROPN
eyereports-42	90	5	,	,	PUNCT
eyereports-42	90	6	shah	shah	PROPN
eyereports-42	90	7	jc	jc	PROPN
eyereports-42	90	8	,	,	PUNCT
eyereports-42	90	9	senapati	senapati	PROPN
eyereports-42	90	10	s	s	PART
eyereports-42	90	11	,	,	PUNCT
eyereports-42	90	12	kompella	kompella	PROPN
eyereports-42	90	13	ub	ub	PROPN
eyereports-42	90	14	.	.	PROPN
eyereports-42	90	15	prediction	prediction	NOUN
eyereports-42	90	16	of	of	ADP
eyereports-42	90	17	vitreal	vitreal	ADJ
eyereports-42	90	18	half	half	ADJ
eyereports-42	90	19	-	-	PUNCT
eyereports-42	90	20	life	life	NOUN
eyereports-42	90	21	based	base	VERB
eyereports-42	90	22	on	on	ADP
eyereports-42	90	23	drug	drug	NOUN
eyereports-42	90	24	physiochemical	physiochemical	ADJ
eyereports-42	90	25	properties	property	NOUN
eyereports-42	90	26	:	:	PUNCT
eyereports-42	90	27	quantitative	quantitative	ADJ
eyereports-42	90	28	structure	structure	NOUN
eyereports-42	90	29	-	-	PUNCT
eyereports-42	90	30	pharmacokinetic	pharmacokinetic	ADJ
eyereports-42	90	31	relationships	relationship	NOUN
eyereports-42	90	32	(	(	PUNCT
eyereports-42	90	33	qspkr	qspkr	PROPN
eyereports-42	90	34	)	)	PUNCT
eyereports-42	90	35	.	.	PUNCT
eyereports-42	91	1	pharm	pharm	NOUN
eyereports-42	91	2	res	re	VERB
eyereports-42	91	3	2009;26:123660	2009;26:123660	NUM
eyereports-42	91	4	.	.	PROPN
eyereports-42	91	5	6	6	NUM
eyereports-42	91	6	.	.	PUNCT
eyereports-42	92	1	mordenti	mordenti	PROPN
eyereports-42	92	2	j	j	PROPN
eyereports-42	92	3	,	,	PUNCT
eyereports-42	92	4	cuthbertson	cuthbertson	PROPN
eyereports-42	92	5	ra	ra	PROPN
eyereports-42	92	6	,	,	PUNCT
eyereports-42	92	7	ferrara	ferrara	NOUN
eyereports-42	92	8	n	n	CCONJ
eyereports-42	92	9	,	,	PUNCT
eyereports-42	92	10	et	et	PROPN
eyereports-42	92	11	al	al	PROPN
eyereports-42	92	12	.	.	PUNCT
eyereports-42	92	13	comparisons	comparison	NOUN
eyereports-42	92	14	of	of	ADP
eyereports-42	92	15	the	the	DET
eyereports-42	92	16	intraocular	intraocular	ADJ
eyereports-42	92	17	tissue	tissue	NOUN
eyereports-42	92	18	distribution	distribution	NOUN
eyereports-42	92	19	,	,	PUNCT
eyereports-42	92	20	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	92	21	,	,	PUNCT
eyereports-42	92	22	and	and	CCONJ
eyereports-42	92	23	safety	safety	NOUN
eyereports-42	92	24	of	of	ADP
eyereports-42	92	25	125i	125i	NOUN
eyereports-42	92	26	-	-	PUNCT
eyereports-42	92	27	labeled	label	VERB
eyereports-42	92	28	full	full	ADJ
eyereports-42	92	29	-	-	PUNCT
eyereports-42	92	30	length	length	NOUN
eyereports-42	92	31	and	and	CCONJ
eyereports-42	92	32	fab	fab	NOUN
eyereports-42	92	33	antibodies	antibody	NOUN
eyereports-42	92	34	in	in	ADP
eyereports-42	92	35	rhesus	rhesus	NOUN
eyereports-42	92	36	monkeys	monkey	NOUN
eyereports-42	92	37	following	follow	VERB
eyereports-42	92	38	intravitreal	intravitreal	ADJ
eyereports-42	92	39	administration	administration	NOUN
eyereports-42	92	40	.	.	PUNCT
eyereports-42	93	1	toxicol	toxicol	PROPN
eyereports-42	93	2	pathol	pathol	NOUN
eyereports-42	93	3	1999	1999	NUM
eyereports-42	93	4	;	;	PUNCT
eyereports-42	93	5	27:536	27:536	NUM
eyereports-42	93	6	-	-	SYM
eyereports-42	93	7	44	44	NUM
eyereports-42	93	8	.	.	PUNCT
eyereports-42	94	1	7	7	X
eyereports-42	94	2	.	.	X
eyereports-42	94	3	bakri	bakri	PROPN
eyereports-42	94	4	sj	sj	PROPN
eyereports-42	94	5	,	,	PUNCT
eyereports-42	94	6	snyder	snyder	PROPN
eyereports-42	94	7	mr	mr	PROPN
eyereports-42	94	8	,	,	PUNCT
eyereports-42	94	9	reid	reid	PROPN
eyereports-42	94	10	jm	jm	PROPN
eyereports-42	94	11	,	,	PUNCT
eyereports-42	94	12	et	et	PROPN
eyereports-42	94	13	al	al	PROPN
eyereports-42	94	14	.	.	PUNCT
eyereports-42	95	1	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	95	2	of	of	ADP
eyereports-42	95	3	intravitreal	intravitreal	ADJ
eyereports-42	95	4	bevacizumab	bevacizumab	NOUN
eyereports-42	95	5	(	(	PUNCT
eyereports-42	95	6	avastin	avastin	PROPN
eyereports-42	95	7	)	)	PUNCT
eyereports-42	95	8	.	.	PUNCT
eyereports-42	96	1	ophthalmology	ophthalmology	NOUN
eyereports-42	96	2	2007	2007	NUM
eyereports-42	96	3	;	;	PUNCT
eyereports-42	96	4	114;855	114;855	NUM
eyereports-42	96	5	-	-	SYM
eyereports-42	96	6	9	9	NUM
eyereports-42	96	7	.	.	NOUN
eyereports-42	96	8	8	8	NUM
eyereports-42	96	9	.	.	X
eyereports-42	97	1	bakri	bakri	PROPN
eyereports-42	97	2	sj	sj	PROPN
eyereports-42	97	3	,	,	PUNCT
eyereports-42	97	4	snyder	snyder	PROPN
eyereports-42	97	5	mr	mr	PROPN
eyereports-42	97	6	,	,	PUNCT
eyereports-42	97	7	reid	reid	PROPN
eyereports-42	97	8	jm	jm	PROPN
eyereports-42	97	9	,	,	PUNCT
eyereports-42	97	10	et	et	PROPN
eyereports-42	97	11	al	al	PROPN
eyereports-42	97	12	.	.	PUNCT
eyereports-42	98	1	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	98	2	of	of	ADP
eyereports-42	98	3	intravitreal	intravitreal	ADJ
eyereports-42	98	4	ranibizu	ranibizu	PROPN
eyereports-42	98	5	mab	mab	PROPN
eyereports-42	98	6	(	(	PUNCT
eyereports-42	98	7	lucentis	lucentis	PROPN
eyereports-42	98	8	)	)	PUNCT
eyereports-42	98	9	.	.	PUNCT
eyereports-42	99	1	ophthalmology	ophthalmology	NOUN
eyereports-42	99	2	2007;114	2007;114	NUM
eyereports-42	99	3	:	:	PUNCT
eyereports-42	99	4	2179	2179	NUM
eyereports-42	99	5	-	-	SYM
eyereports-42	99	6	82	82	NUM
eyereports-42	99	7	.	.	NOUN
eyereports-42	100	1	9	9	NUM
eyereports-42	100	2	.	.	X
eyereports-42	100	3	krohne	krohne	PROPN
eyereports-42	100	4	tu	tu	PROPN
eyereports-42	100	5	,	,	PUNCT
eyereports-42	100	6	eter	eter	NOUN
eyereports-42	100	7	n	n	CCONJ
eyereports-42	100	8	,	,	PUNCT
eyereports-42	100	9	holz	holz	PROPN
eyereports-42	100	10	fg	fg	PROPN
eyereports-42	100	11	,	,	PUNCT
eyereports-42	100	12	meyer	meyer	PROPN
eyereports-42	100	13	ch	ch	PROPN
eyereports-42	100	14	.	.	PUNCT
eyereports-42	101	1	intraocular	intraocular	ADJ
eyereports-42	101	2	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	101	3	of	of	ADP
eyereports-42	101	4	bevacizumab	bevacizumab	NOUN
eyereports-42	101	5	after	after	ADP
eyereports-42	101	6	a	a	DET
eyereports-42	101	7	single	single	ADJ
eyereports-42	101	8	intravitreal	intravitreal	ADJ
eyereports-42	101	9	injection	injection	NOUN
eyereports-42	101	10	in	in	ADP
eyereports-42	101	11	humans	human	NOUN
eyereports-42	101	12	.	.	PUNCT
eyereports-42	102	1	am	be	AUX
eyereports-42	102	2	j	j	PROPN
eyereports-42	102	3	ophthalmol	ophthalmol	PROPN
eyereports-42	102	4	2008	2008	NUM
eyereports-42	102	5	;	;	PUNCT
eyereports-42	102	6	146:508	146:508	PROPN
eyereports-42	102	7	-	-	PUNCT
eyereports-42	102	8	12	12	NUM
eyereports-42	102	9	.	.	PUNCT
eyereports-42	103	1	10	10	NUM
eyereports-42	103	2	.	.	PUNCT
eyereports-42	104	1	zhu	zhu	PROPN
eyereports-42	105	1	q	q	NOUN
eyereports-42	105	2	,	,	PUNCT
eyereports-42	105	3	zeimssen	zeimssen	NOUN
eyereports-42	105	4	f	f	NOUN
eyereports-42	105	5	,	,	PUNCT
eyereports-42	105	6	henke	henke	PROPN
eyereports-42	105	7	-	-	PUNCT
eyereports-42	105	8	fahle	fahle	PROPN
eyereports-42	105	9	s	s	PROPN
eyereports-42	105	10	,	,	PUNCT
eyereports-42	105	11	et	et	PROPN
eyereports-42	105	12	al	al	PROPN
eyereports-42	105	13	.	.	PROPN
eyereports-42	105	14	vitreous	vitreous	ADJ
eyereports-42	105	15	levels	level	NOUN
eyereports-42	105	16	of	of	ADP
eyereports-42	105	17	bevacizumab	bevacizumab	NOUN
eyereports-42	105	18	and	and	CCONJ
eyereports-42	105	19	vascular	vascular	VERB
eyereports-42	105	20	endothelial	endothelial	ADJ
eyereports-42	105	21	growth	growth	NOUN
eyereports-42	105	22	factor	factor	NOUN
eyereports-42	105	23	-	-	PUNCT
eyereports-42	105	24	a	a	NOUN
eyereports-42	105	25	in	in	ADP
eyereports-42	105	26	patients	patient	NOUN
eyereports-42	105	27	with	with	ADP
eyereports-42	105	28	choroidal	choroidal	ADJ
eyereports-42	105	29	neovascularization	neovascularization	NOUN
eyereports-42	105	30	.	.	PUNCT
eyereports-42	106	1	oph	oph	PROPN
eyereports-42	106	2	thalmology	thalmology	PROPN
eyereports-42	106	3	2008;115:1750	2008;115:1750	NUM
eyereports-42	106	4	-	-	SYM
eyereports-42	106	5	5	5	NUM
eyereports-42	106	6	.	.	NOUN
eyereports-42	106	7	11	11	NUM
eyereports-42	106	8	.	.	PUNCT
eyereports-42	107	1	gaudreault	gaudreault	PROPN
eyereports-42	107	2	j	j	PROPN
eyereports-42	107	3	,	,	PUNCT
eyereports-42	107	4	fei	fei	PROPN
eyereports-42	107	5	d	d	PROPN
eyereports-42	107	6	,	,	PUNCT
eyereports-42	107	7	beyer	beyer	PROPN
eyereports-42	107	8	jc	jc	PROPN
eyereports-42	107	9	,	,	PUNCT
eyereports-42	107	10	et	et	PROPN
eyereports-42	107	11	al	al	PROPN
eyereports-42	107	12	.	.	PUNCT
eyereports-42	107	13	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	107	14	and	and	CCONJ
eyereports-42	107	15	distribution	distribution	NOUN
eyereports-42	107	16	of	of	ADP
eyereports-42	107	17	ranibizumab	ranibizumab	NOUN
eyereports-42	107	18	,	,	PUNCT
eyereports-42	107	19	a	a	DET
eyereports-42	107	20	humanized	humanize	VERB
eyereports-42	107	21	antibody	antibody	NOUN
eyereports-42	107	22	fragment	fragment	NOUN
eyereports-42	107	23	directed	direct	VERB
eyereports-42	107	24	against	against	ADP
eyereports-42	107	25	vegf	vegf	PROPN
eyereports-42	107	26	-	-	PUNCT
eyereports-42	107	27	a	a	NOUN
eyereports-42	107	28	,	,	PUNCT
eyereports-42	107	29	following	follow	VERB
eyereports-42	107	30	intravitreal	intravitreal	ADJ
eyereports-42	107	31	administration	administration	NOUN
eyereports-42	107	32	in	in	ADP
eyereports-42	107	33	rabbits	rabbit	NOUN
eyereports-42	107	34	.	.	PUNCT
eyereports-42	107	35	retina	retina	VERB
eyereports-42	107	36	2007;27:1260	2007;27:1260	NUM
eyereports-42	107	37	-	-	SYM
eyereports-42	107	38	6	6	NUM
eyereports-42	107	39	.	.	NOUN
eyereports-42	107	40	12	12	NUM
eyereports-42	107	41	.	.	PUNCT
eyereports-42	108	1	nomoto	nomoto	PROPN
eyereports-42	108	2	h	h	PROPN
eyereports-42	108	3	,	,	PUNCT
eyereports-42	108	4	shiraga	shiraga	PROPN
eyereports-42	108	5	f	f	PROPN
eyereports-42	108	6	,	,	PUNCT
eyereports-42	108	7	kuno	kuno	PROPN
eyereports-42	108	8	n	n	CCONJ
eyereports-42	108	9	,	,	PUNCT
eyereports-42	108	10	et	et	PROPN
eyereports-42	108	11	al	al	PROPN
eyereports-42	108	12	.	.	PROPN
eyereports-42	109	1	phar	phar	PROPN
eyereports-42	109	2	macokinetics	macokinetics	PROPN
eyereports-42	109	3	of	of	ADP
eyereports-42	109	4	bevacizumab	bevacizumab	NOUN
eyereports-42	109	5	after	after	ADP
eyereports-42	109	6	topical	topical	ADJ
eyereports-42	109	7	,	,	PUNCT
eyereports-42	109	8	subconjunctival	subconjunctival	NOUN
eyereports-42	109	9	,	,	PUNCT
eyereports-42	109	10	and	and	CCONJ
eyereports-42	109	11	intravitreal	intravitreal	ADJ
eyereports-42	109	12	administration	administration	NOUN
eyereports-42	109	13	in	in	ADP
eyereports-42	109	14	rabbits	rabbit	NOUN
eyereports-42	109	15	.	.	PUNCT
eyereports-42	110	1	invest	invest	VERB
eyereports-42	110	2	ophthal	ophthal	NOUN
eyereports-42	110	3	mol	mol	ADP
eyereports-42	110	4	vis	vis	X
eyereports-42	110	5	sci	sci	PROPN
eyereports-42	110	6	2009;50:4807	2009;50:4807	PROPN
eyereports-42	110	7	-	-	SYM
eyereports-42	110	8	13	13	NUM
eyereports-42	110	9	.	.	NOUN
eyereports-42	111	1	13	13	NUM
eyereports-42	111	2	.	.	X
eyereports-42	111	3	miyaki	miyaki	PROPN
eyereports-42	111	4	t	t	PROPN
eyereports-42	111	5	,	,	PUNCT
eyereports-42	111	6	sawada	sawada	PROPN
eyereports-42	111	7	o	o	PROPN
eyereports-42	111	8	,	,	PUNCT
eyereports-42	111	9	kakinoki	kakinoki	PROPN
eyereports-42	111	10	m	m	PROPN
eyereports-42	111	11	,	,	PUNCT
eyereports-42	111	12	et	et	PROPN
eyereports-42	111	13	al	al	PROPN
eyereports-42	111	14	.	.	PUNCT
eyereports-42	112	1	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	112	2	of	of	ADP
eyereports-42	112	3	bevacizumab	bevacizumab	NOUN
eyereports-42	112	4	and	and	CCONJ
eyereports-42	112	5	its	its	PRON
eyereports-42	112	6	effect	effect	NOUN
eyereports-42	112	7	on	on	ADP
eyereports-42	112	8	vascular	vascular	ADJ
eyereports-42	112	9	endothelial	endothelial	ADJ
eyereports-42	112	10	growth	growth	NOUN
eyereports-42	112	11	factor	factor	NOUN
eyereports-42	112	12	after	after	ADP
eyereports-42	112	13	intravitreal	intravitreal	ADJ
eyereports-42	112	14	injection	injection	NOUN
eyereports-42	112	15	of	of	ADP
eyereports-42	112	16	bevacizumab	bevacizumab	NOUN
eyereports-42	112	17	in	in	ADP
eyereports-42	112	18	macaque	macaque	ADJ
eyereports-42	112	19	eyes	eye	NOUN
eyereports-42	112	20	.	.	PUNCT
eyereports-42	113	1	invest	invest	VERB
eyereports-42	113	2	ophthal	ophthal	NOUN
eyereports-42	113	3	mol	mol	ADP
eyereports-42	113	4	vis	vis	X
eyereports-42	113	5	sci	sci	PROPN
eyereports-42	113	6	2010;51:1606	2010;51:1606	PROPN
eyereports-42	113	7	-	-	PUNCT
eyereports-42	113	8	8	8	NUM
eyereports-42	113	9	.	.	PUNCT
eyereports-42	114	1	14	14	NUM
eyereports-42	114	2	.	.	PUNCT
eyereports-42	115	1	kim	kim	PROPN
eyereports-42	115	2	h	h	PROPN
eyereports-42	115	3	,	,	PUNCT
eyereports-42	115	4	csaky	csaky	PROPN
eyereports-42	115	5	kg	kg	PROPN
eyereports-42	115	6	,	,	PUNCT
eyereports-42	115	7	chan	chan	PROPN
eyereports-42	115	8	cc	cc	PROPN
eyereports-42	115	9	,	,	PUNCT
eyereports-42	115	10	et	et	PROPN
eyereports-42	115	11	al	al	PROPN
eyereports-42	115	12	.	.	PUNCT
eyereports-42	116	1	the	the	DET
eyereports-42	116	2	pharmacokinetics	pharmacokinetic	NOUN
eyereports-42	116	3	of	of	ADP
eyereports-42	116	4	rituximab	rituximab	NOUN
eyereports-42	116	5	following	follow	VERB
eyereports-42	116	6	an	an	DET
eyereports-42	116	7	intravitreal	intravitreal	ADJ
eyereports-42	116	8	injection	injection	NOUN
eyereports-42	116	9	.	.	PUNCT
eyereports-42	117	1	exp	exp	NOUN
eyereports-42	117	2	eye	eye	NOUN
eyereports-42	117	3	res	re	NOUN
eyereports-42	117	4	2006	2006	NUM
eyereports-42	117	5	;	;	PUNCT
eyereports-42	117	6	82:760	82:760	NUM
eyereports-42	117	7	-	-	SYM
eyereports-42	117	8	6	6	NUM
eyereports-42	117	9	.	.	PUNCT
eyereports-42	118	1	article	article	PROPN
eyereports-42	118	2	non	non	ADJ
eyereports-42	118	3	-co	-co	PROPN
eyereports-42	118	4	mmerc	mmerc	PROPN
eyereports-42	118	5	ial	ial	PROPN
eyereports-42	118	6	us	us	PROPN
eyereports-42	118	7	e	e	NOUN
eyereports-42	118	8	o	o	NOUN
eyereports-42	118	9	nly	nly	ADV